{
    "data": [
        {
            "title": "How Investors May Respond To Sunrun (RUN) Profit Swing and Surging Home Storage Adoption",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Sunrun Inc. has reported its fourth-quarter and full-year 2025 results, with sales reaching US$466.49¬†million for the quarter and US$1.82¬†billion for the year, revenue of US$1.16¬†billion for the quarter and US$2.96¬†billion for the year, and a swing from a multi‚Äëbillion‚Äëdollar net loss in 2024 to net income of US$103.57¬†million for the quarter and US$449.95¬†million for 2025.</li> <li>Beyond the earnings beat, Sunrun‚Äôs growing battery footprint, now more than 217,000 residential systems and a 71% storage attachment rate, underpins its expanding role in grid services, highlighted by a successful distributed power plant season with PG&amp;E that achieved nearly 99% dispatch accuracy across over 1,200 hours.</li> <li>We‚Äôll now examine how Sunrun‚Äôs sharp turnaround to profitability and rising storage attachment rates might reshape its existing investment narrative.</li> </ul><p>Capitalize on the AI infrastructure supercycle with our selection of the <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473744/ai-infrastructure-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">33 best 'picks and shovels' of the AI gold rush</a> converting record-breaking demand into massive cash flow.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Sunrun Investment Narrative Recap</h2><p>To own Sunrun, you need to believe residential solar plus storage can remain attractive even as tax credits phase out and financing stays complex. The latest earnings beat and return to profitability strengthen the case that scale and higher storage attachment can support margins, but the biggest near term swing factor is still access to affordable capital, while long term policy uncertainty around incentives remains a key overhang. This quarter‚Äôs results do not remove those risks, but they do improve Sunrun‚Äôs financial footing.</p> <p>The most relevant recent development is Sunrun‚Äôs completion of the PG&amp;E Local PeakShift Power season, where over 1,000 customer systems delivered nearly 1,200 hours of highly accurate dispatch. Paired with storage attachment rates reaching 71% by year end 2025, this grid services performance gives more substance to the idea that batteries and virtual power plants could become a meaningful earnings driver, potentially offsetting some pressure from expiring tax credits and higher financing costs over time.</p> <p>Yet while the profit rebound is encouraging, investors should also be aware that concentrated policy risk around solar tax credits could still...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/capital-goods/nasdaq-run/sunrun/puusfyum-run-supportive-policy-changes-and-market-demand-will-drive-mixed-outcomes-ahead\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Sunrun (it's free!)</a></p><p>Sunrun's narrative projects $2.9 billion revenue and $465.4 million earnings by 2028.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/capital-goods/nasdaq-run/sunrun/puusfyum-run-supportive-policy-changes-and-market-demand-will-drive-mixed-outcomes-ahead\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Sunrun's forecasts yield a $22.74 fair value</a>, a 11% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/capital-goods/nasdaq-run/sunrun\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"RUN 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/9fa2a4c7-de78-47ca-906e-c5edae8a6116/chart/quote-price\" width=\"746\"/></a><figcaption>RUN 1-Year Stock Price Chart</figcaption></figure> <p>Before this surprise profit, the most bearish analysts assumed almost flat revenue growth near US$2.1 billion and no profitability, so their far more cautious view of Sunrun‚Äôs financing and policy risks may shift meaningfully as investors reassess those assumptions.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/capital-goods/nasdaq-run/sunrun\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 5 other fair value estimates on Sunrun</a> - why the stock might be worth as much as 32% more than the current price!</p><h2>The Verdict Is Yours</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Sunrun research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/capital-goods/nasdaq-run/sunrun\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 2 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/capital-goods/nasdaq-run/sunrun\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Sunrun research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Sunrun's overall financial health at a glance.</li></ul><h2>No Opportunity In Sunrun?</h2><p>Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:</p><ul><li>The future of work is here. Discover the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473746/robotics-andamp-automation-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">29 top robotics and automation stocks</a> leading the charge in AI-driven automation and industrial transformation.</li><li>Uncover the next big thing with <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/472945/elite-penny-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">30 elite penny stocks</a> that balance risk and reward.</li><li>Explore <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/282/quantum-computing-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">23 top quantum computing companies</a> leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 00:11:19",
            "link": "https://simplywall.st/stocks/us/capital-goods/nasdaq-run/sunrun/news/how-investors-may-respond-to-sunrun-run-profit-swing-and-sur",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following New 2026 Revenue Guidance Release",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Amneal Pharmaceuticals recently issued 2026 earnings guidance, projecting net revenue between US$3.05¬†billion and US$3.15¬†billion, alongside heightened attention around its latest quarterly earnings release.</li> <li>This new guidance gives investors a clearer view of management‚Äôs expectations for the scale of Amneal‚Äôs business as it expands across generics, injectables, biosimilars, and specialty products.</li> <li>We‚Äôll now examine how Amneal‚Äôs US$3.05‚Äì3.15¬†billion 2026 revenue outlook may influence the existing investment narrative built around diversification.</li> </ul><p>We've uncovered the <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> yielding 5%+ that don't just survive market storms, but thrive in them.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Amneal Pharmaceuticals Investment Narrative Recap</h2><p>To own Amneal, you need to believe its push across generics, injectables, biosimilars, and specialty products can offset pricing pressure and legal costs while supporting sustainable scale. The new 2026 revenue guidance of US$3.05‚Äì3.15 billion reinforces that diversification story but does not materially change the near term focus on execution in higher margin categories or the key risk around ongoing pricing and regulatory pressures.</p> <p>The most relevant recent announcement here is the nationwide opioids settlement, which commits Amneal to up to US$88.5 million in cash payments and up to US$177.4 million in naloxone product. That settlement helps clarify a major legal overhang just as management is asking investors to weigh its revenue outlook and pipeline against elevated leverage and the cost of maintaining compliance and quality across a broad portfolio.</p> <p>Yet behind this clearer revenue outlook and legal visibility, investors should still be aware of...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals/3tt90axt-amrx-recent-fda-approvals-and-pipeline-launches-will-drive-upside-momentum\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Amneal Pharmaceuticals (it's free!)</a></p><p>Amneal Pharmaceuticals‚Äô narrative projects $3.5 billion revenue and $207.9 million earnings by 2028.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals/3tt90axt-amrx-recent-fda-approvals-and-pipeline-launches-will-drive-upside-momentum\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Amneal Pharmaceuticals' forecasts yield a $15.20 fair value</a>, a 5% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"AMRX 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/de8755ce-faf4-4170-8a24-89d67d81be0e/chart/quote-price\" width=\"746\"/></a><figcaption>AMRX 1-Year Stock Price Chart</figcaption></figure> <p>Three fair value estimates from the Simply Wall St Community span roughly US$11.94 to about US$70 per share, showing how far apart individual views on Amneal‚Äôs potential can be. Against that backdrop, Amneal‚Äôs new 2026 revenue guidance invites you to weigh its diversification catalyst alongside ongoing pricing and regulatory risks that could influence how those projections translate into business performance.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 3 other fair value estimates on Amneal Pharmaceuticals</a> - why the stock might be worth over 4x more than the current price!</p><h2>Form Your Own Verdict</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your Amneal Pharmaceuticals research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals\" rel=\"noopener noreferrer\" target=\"_blank\">4 key rewards and 3 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Amneal Pharmaceuticals research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amneal Pharmaceuticals' overall financial health at a glance.</li></ul><h2>Ready For A Different Approach?</h2><p>Opportunities like this don't last. These are today's most promising picks. Check them out now:</p><ul><li>Capitalize on the AI infrastructure supercycle with our selection of the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473744/ai-infrastructure-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">33 best 'picks and shovels' of the AI gold rush</a> converting record-breaking demand into massive cash flow.</li><li>The latest GPUs need a type of rare earth metal called Dysprosium and there are only <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 companies in the world exploring or producing it</a>. Find the list for free.</li><li>This technology could replace computers: discover <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/282/quantum-computing-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">23 stocks that are working to make quantum computing a reality</a>.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 00:11:19",
            "link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals/news/the-bull-case-for-amneal-pharmaceuticals-amrx-could-change-f-3",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is National Energy Services Reunited (NESR) Share Surge Justified By Recent Valuation Signals",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>This article is designed to help you assess whether National Energy Services Reunited still represents good value after its recent share price run, or whether the excitement has moved ahead of the company‚Äôs fundamentals.</li> <li>The stock last closed at US$25.14, with returns of 3.9% over 7 days, 26.0% over 30 days, 59.2% year to date and 207.7% over the past year, as well as 278.6% over 3 years and 95.0% over 5 years.</li> <li>These moves have put the company on more investors' radar, and they have been looking more closely at how its current price lines up with its underlying worth. That is where a structured valuation review comes in, using multiple methods to see whether the recent share price action still matches the fundamentals.</li> <li>On our Simply Wall St checks, National Energy Services Reunited scores 2 out of 6 on valuation, which you can see in detail in our <a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/energy/nasdaq-nesr/national-energy-services-reunited/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">valuation scorecard</a>. Next we will walk through the different ways investors commonly assess value, before finishing with a more complete way to think about valuation as a whole.</li> </ul> <p>National Energy Services Reunited scores just 2/6 on our valuation checks. See what other red flags we found in the <a class=\"company-report-links\" data-vars-link-type=\"cta_low_value_score\" href=\"https://www.simplywall.st/stocks/us/energy/nasdaq-nesr/national-energy-services-reunited/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">full valuation breakdown</a>.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Approach 1: National Energy Services Reunited Discounted Cash Flow (DCF) Analysis</h2> <p>A Discounted Cash Flow, or DCF, model takes the cash that a company is expected to generate in the future and discounts it back to today to estimate what the entire business could be worth now.</p> <p>For National Energy Services Reunited, the latest twelve month Free Cash Flow is about $153.0 million. The model used here is a 2 Stage Free Cash Flow to Equity approach, which first applies analyst forecasts and then extends those cash flows further out using additional assumptions by Simply Wall St.</p> <p>The projections used in the model include Free Cash Flow of $154.6 million in 2026 and $219.0 million in 2028, with further years out to 2035 based on extrapolated estimates, all in $. When these projected cash flows are discounted back to today, the DCF model arrives at an estimated intrinsic value of about $58.38 per share.</p> <p>Compared with the recent share price of $25.14, this DCF estimate suggests a difference of around 56.9% between the modelled intrinsic value and the current market price.</p> <p><strong>Result: UNDERVALUED (based on this DCF model)</strong></p> <p>Our Discounted Cash Flow (DCF) analysis suggests National Energy Services Reunited is undervalued by 56.9%. Track this in your <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>, or discover <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">54 more high quality undervalued stocks</a>.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/energy/nasdaq-nesr/national-energy-services-reunited/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NESR Discounted Cash Flow as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/7f4533ec-72e9-4bee-b095-b8fa053aca99/chart/dcf?date=2026-02-27\" width=\"746\"/></a><figcaption>NESR Discounted Cash Flow as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"dcf_explainer_cta\" href=\"https://www.simplywall.st/stocks/us/energy/nasdaq-nesr/national-energy-services-reunited/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for National Energy Services Reunited.</a></p> <h2>Approach 2: National Energy Services Reunited Price vs Earnings</h2> <p>For a profitable company, the P/E ratio is a straightforward way to see how much you are paying for each dollar of earnings. This makes it a useful cross check alongside a DCF model. What counts as a ‚Äúnormal‚Äù P/E depends on what the market expects for future earnings growth and how risky those earnings are, with higher expected growth or lower perceived risk usually supporting a higher multiple.</p> <p>National Energy Services Reunited currently trades on a P/E of about 49.6x. That sits above both the Energy Services industry average of roughly 26.6x and the peer group average of about 32.7x. This suggests the market is applying a richer multiple than these broad comparison points.</p> <p>Simply Wall St‚Äôs Fair Ratio for the stock is 25.9x. This is a proprietary estimate of what the P/E might be based on factors such as earnings growth, profit margins, industry, market cap and company specific risks. Because it ties the multiple to these fundamentals, the Fair Ratio can offer a more tailored reference point than a simple peer or industry comparison.</p> <p>When set against the current P/E of 49.6x, the Fair Ratio of 25.9x points to the shares trading on a higher multiple than this framework would suggest.</p> <p><strong>Result: OVERVALUED</strong></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/energy/nasdaq-nesr/national-energy-services-reunited/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqCM:NESR P/E Ratio as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/7f4533ec-72e9-4bee-b095-b8fa053aca99/chart/pe-multiple-vs-industry?date=2026-02-27\" width=\"746\"/></a><figcaption>NasdaqCM:NESR P/E Ratio as at Feb 2026</figcaption></figure> <p>P/E ratios tell one story, but what if the real opportunity lies elsewhere? <a class=\"company-report-links\" data-vars-link-type=\"cta_preferred_multiple_contextual\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">Start investing in legacies, not executives. Discover our 19 top founder-led companies</a>.</p> <h3>Upgrade Your Decision Making: Choose your National Energy Services Reunited Narrative</h3> <p>Earlier we mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you set out your story for National Energy Services Reunited, link that story to a forecast for revenue, earnings and margins, and then see the Fair Value that falls out of those assumptions so you can compare it with the current share price.</p> <p>Instead of only relying on a single P/E or DCF number, a Narrative combines your view of the business with a live model. It updates automatically when new earnings or news arrive, and is available on the Community page where millions of investors share their own versions.</p> <p>For example, one National Energy Services Reunited Narrative might align with the bullish analyst fair value of US$30.00, built around confidence in hydraulic fracturing capacity and MENA contracts. Another could sit nearer the cautious US$10.00 view that focuses on regional concentration and energy transition risks. Seeing those side by side can help you decide whether the current US$25.14 price is above or below the story you find most convincing.</p> <p>For National Energy Services Reunited, here are previews of two leading National Energy Services Reunited narratives that may help frame the discussion:</p> <p><a href=\"/us/energy/nasdaq-nesr/national-energy-services-reunited/lj4o0x5w-rising-mena-demand-will-boost-oilfield-service-expansion-mfij?utm_medium=finance_user&amp;utm_campaign=cta_bull_narrative_link&amp;utm_source=post\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>üêÇ National Energy Services Reunited Bull Case</strong></a></p> <p>Fair value in this bullish narrative: US$30.00 per share</p> <p>Current price vs this fair value: about 16.1% below the narrative fair value</p> <p>Assumed revenue growth used in this narrative: 19.65% a year</p> <ul> <li>Supports a higher fair value case built around hydraulic fracturing scale in Saudi Arabia, contract visibility across MENA and higher profit margins tied to technology and efficiency gains.</li> <li>Assumes National Energy Services Reunited can sustain robust revenue growth and margin expansion, with future earnings and P/E considered consistent with a US$30.00 anchor valuation.</li> <li>Notes meaningful risks from oilfield concentration, regional exposure and capital intensity, so the optimistic outcome still depends on execution and stable operating conditions.</li> </ul> <p><a href=\"/us/energy/nasdaq-nesr/national-energy-services-reunited/1sh65zqm-revenue-recovery-and-sector-rebound-will-drive-long-term-shareholder-returns?utm_medium=finance_user&amp;utm_campaign=cta_bear_narrative_link&amp;utm_source=post\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>üêª National Energy Services Reunited Bear Case</strong></a></p> <p>Fair value in this more cautious narrative: US$22.14 per share</p> <p>Current price vs this fair value: about 13.5% above the narrative fair value</p> <p>Assumed revenue growth used in this narrative: 18.93% a year</p> <ul> <li>Frames the story around solid MENA contracts and Jafurah exposure, but anchors fair value closer to US$22.14, even with updated analyst targets around US$30.</li> <li>Builds in steady revenue growth and margin improvement, while assuming a more modest future P/E multiple compared with the bullish view.</li> <li>Highlights contract concentration, capital demands, working capital strain and long term energy transition as key risks that could keep the share price nearer this fair value.</li> </ul> <p>Viewed together, these narratives provide two different sets of assumptions for National Energy Services Reunited that can be compared with the current US$25.14 share price.</p> <p>Do you think there's more to the story for National Energy Services Reunited? <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative_community\" href=\"https://simplywall.st/stock/NasdaqCM/NESR\" rel=\"noopener noreferrer\" target=\"_blank\">Head over to our Community to see what others are saying!</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/energy/nasdaq-nesr/national-energy-services-reunited\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqCM:NESR 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/7f4533ec-72e9-4bee-b095-b8fa053aca99/chart/quote-price?date=2026-02-27\" width=\"746\"/></a><figcaption>NasdaqCM:NESR 1-Year Stock Price Chart</figcaption></figure> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if National Energy Services Reunited might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/us/energy/nasdaq-nesr/national-energy-services-reunited/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-02-28 00:11:19",
            "link": "https://simplywall.st/stocks/us/energy/nasdaq-nesr/national-energy-services-reunited/news/is-national-energy-services-reunited-nesr-share-surge-justif",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Why Mesoblast (ASX:MSB) Is Down 7.1% After Issuing First Detailed Ryoncil Revenue Guidance",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Mesoblast Limited recently reported half-year 2025 results, with revenue rising to US$51.34 million and net loss and loss per share both narrowing, and subsequently issued fiscal 2026 guidance calling for US$110 million to US$120 million in Ryoncil net revenue.</li> <li>This combination of sharply higher reported revenue and the first detailed full-year outlook for Ryoncil offers investors a clearer view of Mesoblast‚Äôs early commercial trajectory and cost profile.</li> <li>We‚Äôll now examine how Mesoblast‚Äôs new Ryoncil revenue guidance reframes its investment narrative built around cell therapy commercialization and pipeline expansion.</li> </ul><p>Rare earth metals are the new gold rush. Find out which <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 stocks are leading the charge</a>.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Mesoblast Investment Narrative Recap</h2><p>To own Mesoblast today, you need to believe that Ryoncil can scale from a niche pediatric GvHD launch into a broader cell therapy franchise while the company manages ongoing losses and funding needs. The sharp step up in reported revenue and the new US$110 million to US$120 million Ryoncil guidance sharpen the focus on near term execution: can demand ramp fast enough to ease cash burn, and will trial and regulatory timelines hold without costly delays?</p> <p>The half year 2025 results are the most relevant recent announcement here, because they show early financial traction alongside continuing losses. Revenue of US$51.34 million and a reduced but still sizeable net loss of US$40.16 million underscore the tension between growing top line and the risk that R&amp;D and commercial spend remain high if label expansions in adult GvHD, inflammatory bowel disease or chronic low back pain take longer than expected to translate into meaningful sales.</p> <p>Yet against this improving revenue picture, the risk that slower Ryoncil uptake or trial delays could still force fresh capital raises is something investors should be aware of...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/tz4l8krr-update-for-mesoblast\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Mesoblast (it's free!)</a></p><p>Mesoblast's narrative projects $485.4 million revenue and $222.1 million earnings by 2029. This requires 204.5% yearly revenue growth and a $324.2 million earnings increase from -$102.1 million today.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/tz4l8krr-update-for-mesoblast\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Mesoblast's forecasts yield a A$3.83 fair value</a>, a 71% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"ASX:MSB 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/600844ad-7b8f-4b60-be67-41aeee6634b3/chart/quote-price\" width=\"746\"/></a><figcaption>ASX:MSB 1-Year Stock Price Chart</figcaption></figure> <p>The more optimistic analysts were already assuming revenue could reach about US$1.1 billion and earnings about US$585 million by 2028, so compared with the more cautious concerns about cash burn and trial risk, their narrative is far more bullish and you should recognize that views on Mesoblast can differ widely and may shift again after this new Ryoncil guidance.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 17 other fair value estimates on Mesoblast</a> - why the stock might be a potential multi-bagger!</p><h2>The Verdict Is Yours</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your Mesoblast research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 1 important warning sign</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Mesoblast research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Mesoblast's overall financial health at a glance.</li></ul><h2>Interested In Other Possibilities?</h2><p>Opportunities like this don't last. These are today's most promising picks. Check them out now:</p><ul><li>The future of work is here. Discover the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473746/robotics-andamp-automation-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">29 top robotics and automation stocks</a> leading the charge in AI-driven automation and industrial transformation.</li><li>Invest in the nuclear renaissance through our list of <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473644/nuclear-renaissance/global\" rel=\"noopener noreferrer\" target=\"_blank\">84 elite nuclear energy infrastructure plays</a> powering the global AI revolution.</li><li>AI is about to change healthcare. These <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434426/healthcare-ai/au\" rel=\"noopener noreferrer\" target=\"_blank\">10 stocks are working on everything from early diagnostics to drug discovery</a>. The best part - they are all under $10b in market cap - there's still time to get in early.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 00:11:18",
            "link": "https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/why-mesoblast-asxmsb-is-down-71-after-issuing-first-detailed",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Why ServiceTitan (TTAN) Is Up 10.5% After Morgan Stanley Names It A Sector Top Pick",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>In recent weeks, ServiceTitan was highlighted by Wall Street analysts as one of the best beaten down technology names, with Morgan Stanley upgrading it to Overweight and naming it a sector top pick while institutional investors such as Artisan increased their holdings following earlier software weakness.</li> <li>These moves underscore growing institutional and analyst confidence in ServiceTitan‚Äôs vertical software model for trades and its potential to expand across additional end markets and product lines.</li> <li>We‚Äôll now examine how this renewed analyst and institutional confidence, especially Morgan Stanley‚Äôs sector top pick call, could influence ServiceTitan‚Äôs investment narrative.</li> </ul><p>Capitalize on the AI infrastructure supercycle with our selection of the <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473744/ai-infrastructure-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">33 best 'picks and shovels' of the AI gold rush</a> converting record-breaking demand into massive cash flow.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>ServiceTitan Investment Narrative Recap</h2><p>To own ServiceTitan, you have to believe its vertical software can keep becoming the core system of record for trades while its AI, payments and MAX initiatives deepen customer reliance on the platform. The recent analyst upgrade and institutional buying may support sentiment around the near term catalyst of broader MAX and AI Pro adoption, but they do not remove the key risk that these agentic, automated workflows could prove harder for customers to implement at scale.</p> <p>Among recent announcements, the expansion of ServiceTitan‚Äôs AP Automation and fintech suite, including Tap to Pay and integrated financing, ties in most closely with the current bull thesis around usage based payments and higher take rates. If these tools see sustained customer adoption, they could reinforce the catalysts tied to payments and workflow automation that analysts are watching, even as questions about implementation complexity and returns on AI investments remain in focus.</p> <p>Yet behind the renewed optimism, investors should also be aware that the long term bet on AI driven automation and the MAX program could...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/software/nasdaq-ttan/servicetitan/7pmj2q50-update-for-servicetitan\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on ServiceTitan (it's free!)</a></p><p>ServiceTitan's narrative projects $1.5 billion revenue and $188.8 million earnings by 2028. This requires 18.4% yearly revenue growth and about a $486.9 million earnings increase from -$298.1 million today.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/software/nasdaq-ttan/servicetitan/7pmj2q50-update-for-servicetitan\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how ServiceTitan's forecasts yield a $136.33 fair value</a>, a 85% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/software/nasdaq-ttan/servicetitan\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"TTAN 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/254bf5df-024c-4f4c-b03f-feca2d584ec2/chart/quote-price\" width=\"746\"/></a><figcaption>TTAN 1-Year Stock Price Chart</figcaption></figure> <p>Five fair value estimates from the Simply Wall St Community span roughly US$38 to US$136 per share, showing how differently holders view ServiceTitan‚Äôs potential. Against that wide spread, the core debate around whether AI driven automation and MAX can deliver clear, scalable customer ROI becomes a key lens for thinking about the company‚Äôs longer term performance and invites you to compare several alternative viewpoints.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/software/nasdaq-ttan/servicetitan\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 5 other fair value estimates on ServiceTitan</a> - why the stock might be worth 48% less than the current price!</p><h2>Decide For Yourself</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your ServiceTitan research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/software/nasdaq-ttan/servicetitan\" rel=\"noopener noreferrer\" target=\"_blank\">4 key rewards and 2 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/software/nasdaq-ttan/servicetitan\" rel=\"noopener noreferrer\" target=\"_blank\">Our free ServiceTitan research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ServiceTitan's overall financial health at a glance.</li></ul><h2>Ready For A Different Approach?</h2><p>Our top stock finds are flying under the radar-for now. Get in early:</p><ul><li>The latest GPUs need a type of rare earth metal called Dysprosium and there are only <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 companies in the world exploring or producing it</a>. Find the list for free.</li><li>Invest in the nuclear renaissance through our list of <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473644/nuclear-renaissance/global\" rel=\"noopener noreferrer\" target=\"_blank\">84 elite nuclear energy infrastructure plays</a> powering the global AI revolution.</li><li>We've uncovered the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> yielding 5%+ that don't just survive market storms, but thrive in them.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 00:11:18",
            "link": "https://simplywall.st/stocks/us/software/nasdaq-ttan/servicetitan/news/why-servicetitan-ttan-is-up-105-after-morgan-stanley-names-i",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Should Rising Analyst Optimism Around Earnings Shift On Holding‚Äôs (ONON) Long‚ÄëTerm Growth Narrative?",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>In recent days, On Holding attracted heightened attention as UBS and Zacks reiterated very positive views ahead of the company‚Äôs now-past 3 March 2026 earnings release, citing strong consumer momentum, solid revenue growth and earlier earnings surprises. </li> <li>This cluster of upbeat analyst commentary has sharpened focus on how On‚Äôs recent operational performance may be reshaping expectations for its long-term growth profile and profitability. </li> <li>Now, we‚Äôll examine how this rising analyst optimism around operational strength and upcoming results could influence On Holding‚Äôs existing investment narrative. </li> </ul><p>Uncover the next big thing with <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/472945/elite-penny-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">30 elite penny stocks</a> that balance risk and reward.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>On Holding Investment Narrative Recap</h2><p>To own On Holding, you need to believe its premium brand, product innovation and DTC focus can justify a high valuation and support durable growth. The immediate catalyst is the 3 March 2026 Q4 2025 earnings release, which sits at the center of the recent analyst optimism. The biggest near term risk is that expectations for continued revenue and earnings momentum are now elevated, so any disappointment could magnify share price volatility.</p> <p>The most relevant recent announcement is On‚Äôs 10 February 2026 confirmation of its Q4 2025 earnings date. With analysts already highlighting prior earnings surprises and solid revenue growth, this specific release has become a focal point for testing the bullish thesis on margins, DTC progress and international scaling. How the company‚Äôs reported sales and profitability compare with these expectations may either reinforce, or start to question, the current enthusiasm embedded in the shares.</p> <p>Yet beneath the upbeat commentary, the risk that heavy reliance on premium pricing could eventually face pushback is something investors should be aware of...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/consumer-durables/nyse-onon/on-holding/pr8lhrz5-analyst-commentary-reveals-mixed-views-as-on-holding-adjusts-guidance-and-targets\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on On Holding (it's free!)</a></p><p>On Holding‚Äôs narrative projects CHF5.0 billion revenue and CHF561.2 million earnings by 2028. This requires 22.9% yearly revenue growth and an earnings increase of about CHF425 million from CHF135.9 million today.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/consumer-durables/nyse-onon/on-holding/pr8lhrz5-analyst-commentary-reveals-mixed-views-as-on-holding-adjusts-guidance-and-targets\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how On Holding's forecasts yield a $61.90 fair value</a>, a 30% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/consumer-durables/nyse-onon/on-holding\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"ONON 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/30b460e6-f1a8-445d-9f78-310d4e375cd1/chart/quote-price\" width=\"746\"/></a><figcaption>ONON 1-Year Stock Price Chart</figcaption></figure> <p>Some of the most optimistic analysts were assuming revenue could climb toward CHF 5.5 billion and earnings to about CHF 725 million by 2028, which is far more upbeat than consensus and could be challenged if the recent focus on Asia Pacific expansion leaves results more exposed to regional slowdowns or shocks.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/consumer-durables/nyse-onon/on-holding\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 16 other fair value estimates on On Holding</a> - why the stock might be worth just $45.33!</p><h2>The Verdict Is Yours</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your On Holding research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/consumer-durables/nyse-onon/on-holding\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/consumer-durables/nyse-onon/on-holding\" rel=\"noopener noreferrer\" target=\"_blank\">Our free On Holding research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate On Holding's overall financial health at a glance.</li></ul><h2>Contemplating Other Strategies?</h2><p>Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:</p><ul><li>Find <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">54 companies with promising cash flow potential yet trading below their fair value</a>.</li><li>We've uncovered the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> yielding 5%+ that don't just survive market storms, but thrive in them.</li><li>Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 best rare earth metal stocks</a> of the very few that mine this essential strategic resource.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-02-28 00:06:08",
            "link": "https://simplywall.st/stocks/us/consumer-durables/nyse-onon/on-holding/news/should-rising-analyst-optimism-around-earnings-shift-on-hold",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "SentinelOne Unveils Identity Platform As Market Weighs Losses And Valuation",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>SentinelOne (NYSE:S) has launched a next generation identity security platform focused on protecting both human users and AI agent accounts.</li> <li>The new offering shifts from traditional authentication checks to continuous, behavior based validation and runtime authorization withdrawal.</li> <li>The move targets rising identity centric threats as enterprises adopt more automation and AI driven workflows.</li> </ul> <p>SentinelOne enters this launch with shares at $13.48 and a mixed recent track record, including a 10.8% decline over the past 30 days and a 33.7% decline over the past year. For investors following NYSE:S, the new platform reflects how the company is trying to position itself in identity security as attack surfaces evolve.</p> <p>For investors and customers, the key question is how much demand develops for identity protection that explicitly includes AI agents alongside human users. This release also indicates where SentinelOne is focusing its product roadmap, which may influence how its role within broader cybersecurity exposure in a portfolio is evaluated.</p> <p>Stay updated on the most important news stories for <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://www.simplywall.st/stocks/us/software/nyse-s/sentinelone/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">SentinelOne</a> by adding it to your <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>. Alternatively, explore our <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/stock/NYSE/S\" rel=\"noopener noreferrer\" target=\"_blank\">Community</a> to discover new perspectives on SentinelOne.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/us/software/nyse-s/sentinelone/future\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:S Earnings &amp; Revenue Growth as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/f2abf38f-6e34-40bd-a59e-9d368e694ec3/chart/earnings-and-revenue-growth?date=2026-02-27\" width=\"746\"/></a><figcaption>NYSE:S Earnings &amp; Revenue Growth as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_news_risk_alert\" href=\"https://www.simplywall.st/stocks/us/software/nyse-s/sentinelone\" rel=\"noopener noreferrer\" target=\"_blank\">We've flagged 2 risks for SentinelOne. See which could impact your investment.</a></p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>Quick Assessment</h3> <ul> <li><strong>‚úÖ Price vs Analyst Target</strong>: At $13.48 versus an average analyst target of $20.71, the price sits about 35% below consensus expectations.</li> <li><strong>‚úÖ Simply Wall St Valuation</strong>: Shares are described as trading 44.4% below an estimated fair value, which flags potential upside based on that model.</li> <li><strong>‚ùå Recent Momentum</strong>: The stock has a 30 day return of about 10.8% decline, so the market has been cautious recently.</li> </ul> <p>There is only one way to know the right time to buy, sell or hold SentinelOne: head to Simply Wall St's\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/software/nyse-s/sentinelone/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">company report for the latest analysis of SentinelOne's Fair Value</a>.</p> <h3>Key Considerations</h3> <ul> <li>üìä The new identity platform extends SentinelOne's reach into protecting both human and AI agent accounts, which could broaden its role in zero trust and automation heavy environments.</li> <li>üìä Keep an eye on customer adoption, any commentary on AI related deal wins, and whether revenue of US$955.65m starts to reflect traction from this product line.</li> <li>‚ö†Ô∏è The company is currently loss making with net income of a US$411.29m loss and is flagged as not forecast to reach profitability within 3 years, so funding and cash burn remain key watchpoints.</li> </ul> <h3>Dig Deeper</h3> <p>For the full picture including more risks and rewards, check out the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/software/nyse-s/sentinelone\" rel=\"noopener noreferrer\" target=\"_blank\">complete SentinelOne analysis</a>. Alternatively, you can visit the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stock/NYSE/S\" rel=\"noopener noreferrer\" target=\"_blank\">community page for SentinelOne</a> to see how other investors believe this latest news will impact the company's narrative.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 00:06:08",
            "link": "https://simplywall.st/stocks/us/software/nyse-s/sentinelone/news/sentinelone-unveils-identity-platform-as-market-weighs-losse",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is Earnings Beat And New Audit Voice Altering The Investment Case For Darling Ingredients (DAR)?",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Darling Ingredients recently reported quarterly revenues that came in well above analyst expectations, with management highlighting strong operational execution, EBITDA growth and improved gross margins despite industry headwinds.</li> <li>The company also disclosed a planned 2026 retirement of long-time lead director Gary Mize and the immediate addition of former Cargill executive Robert Aspell to the board and Audit Committee, potentially sharpening oversight around global agriculture exposure and risk management.</li> <li>Against this backdrop of earnings outperformance and fresh audit expertise from Robert Aspell, we‚Äôll assess how Darling Ingredients‚Äô investment narrative may evolve.</li> </ul><p>Invest in the nuclear renaissance through our list of <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473644/nuclear-renaissance/global\" rel=\"noopener noreferrer\" target=\"_blank\">84 elite nuclear energy infrastructure plays</a> powering the global AI revolution.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Darling Ingredients Investment Narrative Recap</h2><p>To own Darling Ingredients, you need to believe its mix of rendering, renewable fuels and specialty ingredients can translate volatile inputs and policy swings into steadier cash generation. The latest revenue beat and margin improvement support that thesis, but do not materially change the near term focus on renewable fuel policy clarity as the key catalyst, or on weak recent profitability and high leverage as central risks.</p> <p>The most relevant development for that near term story is the board change. Adding former Cargill executive Robert Aspell, with deep global agriculture and risk experience, to the Audit Committee could sharpen oversight around feedstock exposure, capital allocation and compliance just as Darling works through margin volatility and balance sheet constraints in its Fuel and Feed segments.</p> <p>Yet against the recent earnings volatility and tight interest coverage, one area investors should be especially aware of is the risk that prolonged regulatory uncertainty could...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/food-beverage-tobacco/nyse-dar/darling-ingredients/m6tj1w9q-us-renewable-mandates-and-specialty-ingredients-will-power-market-evolution-ybid\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Darling Ingredients (it's free!)</a></p><p>Darling Ingredients' narrative projects $6.5 billion revenue and $673.1 million earnings by 2028.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/food-beverage-tobacco/nyse-dar/darling-ingredients/m6tj1w9q-us-renewable-mandates-and-specialty-ingredients-will-power-market-evolution-ybid\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Darling Ingredients' forecasts yield a $47.46 fair value</a>, a 10% downside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-dar/darling-ingredients\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"DAR 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/ddd8b6e1-179a-4580-91d0-0fba71c1152c/chart/quote-price\" width=\"746\"/></a><figcaption>DAR 1-Year Stock Price Chart</figcaption></figure> <p>Some of the most optimistic analysts expect revenue near US$6.8 billion and earnings around US$891.1 million by 2028, whereas concerns about rising capex and regulatory dependence paint a much tougher picture, and this quarter‚Äôs earnings beat and governance changes could ultimately shift how you weigh those competing views.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/food-beverage-tobacco/nyse-dar/darling-ingredients\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 3 other fair value estimates on Darling Ingredients</a> - why the stock might be worth 10% less than the current price!</p><h2>The Verdict Is Yours</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your Darling Ingredients research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-dar/darling-ingredients\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 4 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-dar/darling-ingredients\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Darling Ingredients research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Darling Ingredients' overall financial health at a glance.</li></ul><h2>Contemplating Other Strategies?</h2><p>Our daily scans reveal stocks with breakout potential. Don't miss this chance:</p><ul><li>Find <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">54 companies with promising cash flow potential yet trading below their fair value</a>.</li><li>We've uncovered the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> yielding 5%+ that don't just survive market storms, but thrive in them.</li><li>Capitalize on the AI infrastructure supercycle with our selection of the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473744/ai-infrastructure-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">33 best 'picks and shovels' of the AI gold rush</a> converting record-breaking demand into massive cash flow.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 00:06:08",
            "link": "https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-dar/darling-ingredients/news/is-earnings-beat-and-new-audit-voice-altering-the-investment",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Assessing Lithia Motors (LAD) Valuation After Recent Share Price Pullback",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Why Lithia Motors stock is drawing attention now</h2> <p>Lithia Motors (LAD) has been on many investors‚Äô radar after recent share performance, with the stock showing a negative move over the month and past 3 months, prompting closer scrutiny of its current valuation.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/retail/nyse-lad/lithia-motors\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Lithia Motors.</a></p> <p>At a share price of $281.46, Lithia Motors has seen a 1 day share price return of 0.69%, set against a weaker 30 day share price return of 13.97% and a 1 year total shareholder return of 17.7%. Together, these figures point to fading momentum after earlier gains over three years.</p> <p>If this pullback has you thinking about where else capital could work harder, it might be a good time to broaden your search with our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_founder_led\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">19 top founder-led companies</a>.</p> <p>With Lithia trading at $281.46, an indicated 58.71% discount to one intrinsic value estimate and a 39.81% discount to the average analyst target of $393.50, you have to ask: is this a genuine opportunity, or is the market already factoring in future growth?</p> <h2>Most Popular Narrative: 28.7% Undervalued</h2> <p>On the most followed narrative, Lithia Motors' fair value of $394.57 sits well above the current $281.46 share price, which puts a lot of focus on what is driving that gap.</p> <blockquote> <p><em>Ongoing technology investments, especially the full rollout of Pinewood.AI, are expected to materially lower SG&amp;A through automation, unified workflows, and improved productivity, driving operating leverage that should improve net margins and efficiency ratios over the next several years.</em></p> </blockquote> <p><em><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/g0g50k5y-analysts-lift-lithia-motors-price-target-as-buybacks-and-expansions-drive-improved-margins\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></em></p> <p>If you want to see what is really baked into that valuation, the core of this narrative is a specific mix of revenue growth, margin uplift, and future earnings multiples that are anything but conservative.</p> <p><strong>Result: Fair Value of $394.57 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/g0g50k5y-analysts-lift-lithia-motors-price-target-as-buybacks-and-expansions-drive-improved-margins\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, you also have to keep an eye on risks such as elevated acquisition costs or weaker organic store performance, which could challenge those margin and earnings assumptions.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/retail/nyse-lad/lithia-motors\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Lithia Motors narrative.</a></p> <h2>Next Steps</h2> <p>With both risks and rewards on the table, what matters most is how you weigh them for your own portfolio. Take a closer look at the full picture and let the data guide your stance through <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/retail/nyse-lad/lithia-motors\" rel=\"noopener noreferrer\" target=\"_blank\">5 key rewards and 1 important warning sign</a>.</p> <h2>Looking for more investment ideas?</h2> <p>If Lithia has sparked new questions about where your money works hardest, do not stop here. Let the screener surface fresh angles you might be missing.</p> <ul> <li>Target potential value opportunities by scanning companies on our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">54 high quality undervalued stocks</a> and see which ones match your return expectations and risk comfort.</li> <li>Prioritise stability by reviewing companies highlighted in the <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/us\" rel=\"noopener noreferrer\" target=\"_blank\">80 resilient stocks with low risk scores</a>, so you can focus on businesses with lower overall risk scores.</li> <li>Hunt for lesser known prospects through our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/us\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 24 high quality undiscovered gems</a> and spot companies that may not yet be widely followed.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-02-28 00:06:08",
            "link": "https://simplywall.st/stocks/us/retail/nyse-lad/lithia-motors/news/assessing-lithia-motors-lad-valuation-after-recent-share-pri-1",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is Iovance Biotherapeutics (IOVA) Attractive After Recent 33% Weekly Share Price Jump",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>If you are wondering whether Iovance Biotherapeutics at around US$3.79 is a bargain or a value trap, you are not alone. This article will walk through what the current price could mean for you.</li> <li>The stock has recently moved sharply, with a 33% return over the last 7 days, 27.2% over the last 30 days, and 50.4% year to date, even though the 1 year, 3 year and 5 year returns remain negative.</li> <li>These swings have come as investors react to ongoing developments around Iovance Biotherapeutics and its pipeline, which can quickly change sentiment around early stage biotech names. Understanding what is already baked into the share price matters if you are trying to work out whether recent moves reflect lasting shifts in expectations or short term trading.</li> <li>On our valuation checks the company scores <a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">4 out of 6</a> for being undervalued. Next we will look at how different valuation approaches line up on Iovance Biotherapeutics, and then finish with a way to put those numbers into a fuller investment story.</li> </ul> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_industry_underperformer\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/future\" rel=\"noopener noreferrer\" target=\"_blank\">Find out why Iovance Biotherapeutics's -27.9% return over the last year is lagging behind its peers.</a></p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Approach 1: Iovance Biotherapeutics Discounted Cash Flow (DCF) Analysis</h2> <p>A Discounted Cash Flow, or DCF, model takes estimates of a company‚Äôs future cash flows and discounts them back to today to arrive at an estimate of what the business could be worth right now.</p> <p>For Iovance Biotherapeutics, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in US$. The latest twelve month free cash flow is a loss of about $343.7 million. Analysts provide forecasts out to 2030, with free cash flow projections moving from a loss of $146 million in 2026 and $13 million in 2027, to positive cash flows of $143 million in 2028, $231 million in 2029 and $313 million in 2030. Beyond the analyst horizon, Simply Wall St extrapolates further free cash flow estimates out to 2035 using its own growth assumptions.</p> <p>When all of those projected cash flows are discounted back to today, the DCF model arrives at an estimated intrinsic value of about $23.63 per share. Compared with the recent share price around $3.79, this implies the stock is about 84.0% undervalued on this measure.</p> <p><strong>Result: UNDERVALUED</strong></p> <p>Our Discounted Cash Flow (DCF) analysis suggests Iovance Biotherapeutics is undervalued by 84.0%. Track this in your <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>, or discover <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">54 more high quality undervalued stocks</a>.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"IOVA Discounted Cash Flow as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/af2848b1-cfd3-42ac-adb3-fafd0b7d60eb/chart/dcf?date=2026-02-27\" width=\"746\"/></a><figcaption>IOVA Discounted Cash Flow as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"dcf_explainer_cta\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Iovance Biotherapeutics.</a></p> <h2>Approach 2: Iovance Biotherapeutics Price vs Sales</h2> <p>For companies that are not yet profitable, the P/S ratio is often more useful than P/E because it compares what investors are paying to the revenue being generated, rather than to earnings that are still negative.</p> <p>In general, higher expected growth and lower perceived risk can support a higher P/S ratio. Slower growth or higher risk tends to justify a lower one. That is why it helps to look at Iovance Biotherapeutics in the context of both its industry and its own fundamentals.</p> <p>Iovance Biotherapeutics currently trades on a P/S of 5.93x. This sits below the Biotechs industry average of 12.58x and also below the peer average of 6.82x provided. Simply Wall St‚Äôs Fair Ratio for the company is 4.19x, which is an estimate of the P/S multiple that might be reasonable given factors such as earnings growth, profit margins, industry, market cap and specific risks. Compared with simple peer or industry comparisons, the Fair Ratio aims to be more tailored to the company‚Äôs profile.</p> <p>Putting that together, Iovance Biotherapeutics‚Äô actual P/S of 5.93x is above the Fair Ratio of 4.19x, which points to the shares pricing in a richer multiple than this framework suggests.</p> <p><strong>Result: OVERVALUED</strong></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGM:IOVA P/S Ratio as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/af2848b1-cfd3-42ac-adb3-fafd0b7d60eb/chart/ps-multiple-vs-industry?date=2026-02-27\" width=\"746\"/></a><figcaption>NasdaqGM:IOVA P/S Ratio as at Feb 2026</figcaption></figure> <p>P/S ratios tell one story, but what if the real opportunity lies elsewhere? <a class=\"company-report-links\" data-vars-link-type=\"cta_preferred_multiple_contextual\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">Start investing in legacies, not executives. Discover our 19 top founder-led companies</a>.</p> <h3>Upgrade Your Decision Making: Choose your Iovance Biotherapeutics Narrative</h3> <p>Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, which are simply your story about Iovance Biotherapeutics tied directly to numbers like future revenue, earnings, margins and a fair value estimate.</p> <p>On Simply Wall St‚Äôs Community page, millions of investors use Narratives as an accessible tool to connect a company‚Äôs story to a financial forecast and then to a fair value. This allows you to compare that fair value with the current share price to help decide if the stock looks attractive or stretched on your assumptions.</p> <p>Because Narratives update automatically when new information such as company announcements, earnings or analyst revisions appear, you are not locked into a static view. You can quickly see how fresh data shifts the fair value output linked to your story.</p> <p>For Iovance Biotherapeutics, one investor might build a cautious Narrative anchored around a US$1.00 fair value while another might build an optimistic Narrative around US$20.00. By setting out the revenue, earnings and P/E assumptions behind each, you can decide which version feels closer to your own view or adjust the inputs to create something in between.</p> <p>For Iovance Biotherapeutics, we will make it easy for you with previews of two leading Iovance Biotherapeutics Narratives:</p> <p><a href=\"/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/13svd0s7-amtagvi-and-new-til-will-meet-aging-global-demand?utm_medium=finance_user&amp;utm_campaign=cta_bull_narrative_link&amp;utm_source=post\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>üêÇ Iovance Biotherapeutics Bull Case</strong></a></p> <p>Fair value in this bullish narrative: US$17.00 per share</p> <p>Implied discount to this fair value versus the recent US$3.79 share price: about 78% below the narrative fair value</p> <p>Revenue growth assumption in this narrative: 56.96% a year</p> <ul> <li>Assumes Amtagvi adoption, broader patient access, and efficiency gains support higher revenue and a turnaround from losses to profit over the next few years.</li> <li>Builds in a higher profit margin and a future P/E of 75.10x, which is well above the current US Biotechs industry P/E referenced earlier in the article.</li> <li>Anchors on a Fair Value of US$17.00, based on bullish analyst assumptions for revenue of US$1.0b and earnings of US$126.3m by 2028, discounted back at about 7.11%.</li> </ul> <p><a href=\"/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/jv6qnzu7-rising-interest-rates-and-dilution-will-stifle-til-progress?utm_medium=finance_user&amp;utm_campaign=cta_bear_narrative_link&amp;utm_source=post\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>üêª Iovance Biotherapeutics Bear Case</strong></a></p> <p>Fair value in this bearish narrative: US$2.00 per share</p> <p>Implied premium to this fair value versus the recent US$3.79 share price: about 89% above the narrative fair value</p> <p>Revenue growth assumption in this narrative: 43.28% a year</p> <ul> <li>Assumes slower commercialization, high costs, complex distribution, and pressure from drug pricing scrutiny and interest rates, with continued execution risk.</li> <li>Uses a lower profit margin of 3.20% and a future P/E of 50.65x, while still baking in material revenue growth from Amtagvi and the pipeline.</li> <li>Arrives at a Fair Value of US$2.00 per share, reflecting a cautious view that the market may be pricing in more growth and profitability than these assumptions support.</li> </ul> <p>Together, these Narratives frame the recent US$3.79 share price between a bullish fair value of US$17.00 and a bearish fair value of US$2.00. Your job is to decide which story, or something in between, best fits your own expectations for Iovance Biotherapeutics.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_generic_community_narrative\" href=\"https://simplywall.st/features/community-narratives\" rel=\"noopener noreferrer\" target=\"_blank\">Curious how numbers become stories that shape markets? Explore Community Narratives</a></p> <p>Do you think there's more to the story for Iovance Biotherapeutics? <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative_community\" href=\"https://simplywall.st/stock/NasdaqGM/IOVA\" rel=\"noopener noreferrer\" target=\"_blank\">Head over to our Community to see what others are saying!</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGM:IOVA 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/af2848b1-cfd3-42ac-adb3-fafd0b7d60eb/chart/quote-price?date=2026-02-27\" width=\"746\"/></a><figcaption>NasdaqGM:IOVA 1-Year Stock Price Chart</figcaption></figure> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-02-28 00:06:08",
            "link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/news/is-iovance-biotherapeutics-iova-attractive-after-recent-33-w",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is It Too Late To Consider Sumitomo Metal Mining (TSE:5713) After A 1-Year Tripling?",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>If you are trying to figure out whether Sumitomo Metal Mining is priced attractively or stretched at its current level, you are in the right place for a clear look at what the market might be implying.</li> <li>The share price last closed at ¬•12,650, with returns of 26.4% over 7 days, 40.5% over 30 days, 90.6% year to date and 297.4% over 1 year. This naturally raises questions about growth potential and changes in perceived risk.</li> <li>Recent news around the metals and mining sector, including attention on materials linked to energy transition themes and supply security, has kept investors focused on companies like Sumitomo Metal Mining. This backdrop helps frame the strong recent returns and why market expectations may have shifted.</li> <li>Despite that, our valuation checklist gives Sumitomo Metal Mining a score of <a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/jp/materials/tse-5713/sumitomo-metal-mining-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">0 out of 6</a> for being undervalued. We will therefore run through standard valuation approaches next and then finish by looking at a broader way to think about what this price might really mean.</li> </ul> <p>Sumitomo Metal Mining scores just 0/6 on our valuation checks. See what other red flags we found in the <a class=\"company-report-links\" data-vars-link-type=\"cta_low_value_score\" href=\"https://www.simplywall.st/stocks/jp/materials/tse-5713/sumitomo-metal-mining-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">full valuation breakdown</a>.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Approach 1: Sumitomo Metal Mining Discounted Cash Flow (DCF) Analysis</h2> <p>A Discounted Cash Flow, or DCF, model takes estimates of the cash a company might generate in the future and discounts those amounts back into today‚Äôs money, aiming to arrive at an intrinsic value per share.</p> <p>For Sumitomo Metal Mining, the latest twelve month free cash flow sits at ¬•35,458.50m. Analysts provide explicit free cash flow estimates for the next few years, and Simply Wall St then extends those projections further out. In this case, free cash flow is projected at ¬•82,950.00m by the year ending March 2030, with ten year forecasts combining analyst inputs for the nearer years and extrapolated estimates thereafter. All figures are expressed in ¬• and discounted using a 2 Stage Free Cash Flow to Equity approach.</p> <p>On this basis, the DCF model arrives at an estimated intrinsic value of about ¬•6,259 per share. Compared with the recent share price of ¬•12,650, the model implies the stock is around 102.1% above this estimate, which points to a valuation that is rich relative to these cash flow assumptions.</p> <p><strong>Result: OVERVALUED</strong></p> <p>Our Discounted Cash Flow (DCF) analysis suggests Sumitomo Metal Mining may be overvalued by 102.1%. <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_overvalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/jp\" rel=\"noopener noreferrer\" target=\"_blank\">Discover 20 high quality undervalued stocks</a> or <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_overvalued\" href=\"https://simplywall.st/features/stock-screener\" rel=\"noopener noreferrer\" target=\"_blank\">create your own screener</a> to find better value opportunities.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/jp/materials/tse-5713/sumitomo-metal-mining-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"5713 Discounted Cash Flow as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/da29ae93-0c5f-4fe7-ba99-48a8c104a1f7/chart/dcf?date=2026-02-27\" width=\"746\"/></a><figcaption>5713 Discounted Cash Flow as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"dcf_explainer_cta\" href=\"https://www.simplywall.st/stocks/jp/materials/tse-5713/sumitomo-metal-mining-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Sumitomo Metal Mining.</a></p> <h2>Approach 2: Sumitomo Metal Mining Price vs Earnings</h2> <p>For a profitable company, the P/E ratio is a useful way to think about what you are paying for each unit of earnings. A higher P/E usually reflects higher market expectations for future earnings or a lower perceived risk, while a lower P/E often aligns with more modest expectations or higher perceived risk.</p> <p>Sumitomo Metal Mining currently trades on a P/E of 36.0x. That sits above the Metals and Mining industry average P/E of 14.5x and also above the peer group average of 34.9x. On simple comparisons, the market is assigning a richer earnings multiple to the stock than to the broader industry and its peer set.</p> <p>Simply Wall St‚Äôs Fair Ratio for Sumitomo Metal Mining is 21.7x. This is a proprietary estimate of what a more ‚Äúnormal‚Äù P/E might look like for the company, taking into account factors such as earnings growth profile, profit margins, size, industry and stock specific risks. Because it blends these elements rather than relying only on broad peer or industry averages, the Fair Ratio can provide a more tailored reference point.</p> <p>Comparing the Fair Ratio of 21.7x with the current P/E of 36.0x suggests the shares are trading well above this earnings based reference level.</p> <p><strong>Result: OVERVALUED</strong></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/jp/materials/tse-5713/sumitomo-metal-mining-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"TSE:5713 P/E Ratio as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/da29ae93-0c5f-4fe7-ba99-48a8c104a1f7/chart/pe-multiple-vs-industry?date=2026-02-27\" width=\"746\"/></a><figcaption>TSE:5713 P/E Ratio as at Feb 2026</figcaption></figure> <p>P/E ratios tell one story, but what if the real opportunity lies elsewhere? <a class=\"company-report-links\" data-vars-link-type=\"cta_preferred_multiple_contextual\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/jp\" rel=\"noopener noreferrer\" target=\"_blank\">Start investing in legacies, not executives. Discover our 12 top founder-led companies</a>.</p> <h3>Upgrade Your Decision Making: Choose your Sumitomo Metal Mining Narrative</h3> <p>Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, a simple way for you to connect your view of Sumitomo Metal Mining with the numbers that sit behind fair value estimates.</p> <p>A Narrative is your story for the company, where you spell out what you believe about its future revenue, earnings and margins, then tie that story directly to a financial forecast and an implied fair value.</p> <p>On Simply Wall St, Narratives are available to you on the Community page, where millions of investors share these story plus numbers views. This can help you see how different assumptions translate into different fair values.</p> <p>Once you have a Narrative, you can compare its Fair Value to the current share price. This can help you decide whether the market price looks attractive, stretched or somewhere in between, based on your own assumptions rather than only a single model output.</p> <p>Narratives also update when new information such as news or earnings is added to the platform, so your story and fair value can stay aligned with the latest data instead of becoming stale.</p> <p>For Sumitomo Metal Mining, one investor might build a Narrative with relatively cautious revenue growth and margins, while another might assume stronger demand and profitability. The Community page allows you to see how those different inputs lead to different fair values.</p> <p>Do you think there's more to the story for Sumitomo Metal Mining? <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative_community\" href=\"https://simplywall.st/stock/TSE/5713\" rel=\"noopener noreferrer\" target=\"_blank\">Head over to our Community to see what others are saying!</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/jp/materials/tse-5713/sumitomo-metal-mining-shares\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"TSE:5713 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/da29ae93-0c5f-4fe7-ba99-48a8c104a1f7/chart/quote-price?date=2026-02-27\" width=\"746\"/></a><figcaption>TSE:5713 1-Year Stock Price Chart</figcaption></figure> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 00:00:55",
            "link": "https://simplywall.st/stocks/jp/materials/tse-5713/sumitomo-metal-mining-shares/news/is-it-too-late-to-consider-sumitomo-metal-mining-tse5713-aft-1",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is HA Sustainable Infrastructure Capital (HASI) Pricing Reflect Its Strong Recent Share Price Performance",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>If you are wondering whether HA Sustainable Infrastructure Capital is priced fairly today, you are not alone. This article is designed to help you weigh up what you are really paying for.</li> <li>The stock recently closed at US$36.85, with returns of 7.2% over 30 days, 15.8% year to date, 36.9% over 1 year and 41.9% over 3 years, while the 5 year return sits at an 11.4% decline. These figures can change how investors think about both upside potential and risk.</li> <li>Recent news around the broader sustainable infrastructure space has kept attention on companies like HA Sustainable Infrastructure Capital, as investors assess how funding conditions, policy support and project pipelines might affect long term cash flows. This context helps explain why the share price has moved over different time frames, even without company specific headlines dominating the news cycle.</li> <li>Right now the company scores 2 out of 6 on our valuation checks, giving it a value score of <a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/diversified-financials/nyse-hasi/ha-sustainable-infrastructure-capital/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">2</a>. Next we will look at what different valuation approaches say about that number, before finishing with an even more complete way to think about what the stock is really worth.</li> </ul> <p>HA Sustainable Infrastructure Capital scores just 2/6 on our valuation checks. See what other red flags we found in the <a class=\"company-report-links\" data-vars-link-type=\"cta_low_value_score\" href=\"https://www.simplywall.st/stocks/us/diversified-financials/nyse-hasi/ha-sustainable-infrastructure-capital/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">full valuation breakdown</a>.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>Approach 1: HA Sustainable Infrastructure Capital Excess Returns Analysis</h3> <p>The Excess Returns model asks a simple question: are shareholders earning more on the company‚Äôs equity than the return they are assumed to require, and for how long can that continue?</p> <p>For HA Sustainable Infrastructure Capital, the model starts with a Book Value of US$20.25 per share and a Stable EPS of US$3.66 per share, based on weighted future Return on Equity estimates from 6 analysts. That implies an average Return on Equity of 15.62% on a Stable Book Value of US$23.44 per share, which comes from estimates by 5 analysts.</p> <p>The required return for shareholders, or Cost of Equity, is set at US$2.19 per share. The difference between what the company is expected to earn and this required return is the Excess Return, estimated at US$1.47 per share. The model then projects these excess returns forward and discounts them back to arrive at an intrinsic value of about US$48.13 per share.</p> <p>Against the recent share price of US$36.85, this implies the stock is around 23.4% undervalued on this measure.</p> <p><strong>Result: UNDERVALUED</strong></p> <p>Our Excess Returns analysis suggests HA Sustainable Infrastructure Capital is undervalued by 23.4%. Track this in your <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>, or discover <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">54 more high quality undervalued stocks</a>.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/diversified-financials/nyse-hasi/ha-sustainable-infrastructure-capital/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"HASI Discounted Cash Flow as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/16359f8c-34f4-4302-89a7-1159e60d9e78/chart/dcf?date=2026-02-27\" width=\"746\"/></a><figcaption>HASI Discounted Cash Flow as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"dcf_explainer_cta\" href=\"https://www.simplywall.st/stocks/us/diversified-financials/nyse-hasi/ha-sustainable-infrastructure-capital/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for HA Sustainable Infrastructure Capital.</a></p> <h3>Approach 2: HA Sustainable Infrastructure Capital Price vs Earnings</h3> <p>For a profitable company like HA Sustainable Infrastructure Capital, the P/E ratio is a useful way to relate what you are paying per share to the earnings that support that price. It gives you a quick sense of how many years of current earnings the market is effectively pricing in.</p> <p>What counts as a \"normal\" P/E depends a lot on growth expectations and risk. Higher expected earnings growth or more predictable cash flows can justify a higher P/E, while slower growth or higher risk usually point to a lower, more cautious multiple.</p> <p>Right now, HA Sustainable Infrastructure Capital trades on a P/E of 23.97x. That sits above the Diversified Financial industry average of about 16.57x and above the peer average of 10.99x, so on simple comparisons the shares look more expensive than many alternatives.</p> <p>Simply Wall St‚Äôs Fair Ratio is designed to refine that picture. Its Fair P/E of 15.36x for HA Sustainable Infrastructure Capital reflects factors like earnings growth, profit margins, industry, market cap and company specific risks, rather than just broad peer or industry groupings. Because it ties the multiple directly to these fundamentals, it can provide a more tailored benchmark than raw averages.</p> <p>Comparing the current P/E of 23.97x with the Fair Ratio of 15.36x suggests the shares are pricing in more optimism than the model implies.</p> <p><strong>Result: OVERVALUED</strong></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/diversified-financials/nyse-hasi/ha-sustainable-infrastructure-capital/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:HASI P/E Ratio as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/16359f8c-34f4-4302-89a7-1159e60d9e78/chart/pe-multiple-vs-industry?date=2026-02-27\" width=\"746\"/></a><figcaption>NYSE:HASI P/E Ratio as at Feb 2026</figcaption></figure> <p>P/E ratios tell one story, but what if the real opportunity lies elsewhere? <a class=\"company-report-links\" data-vars-link-type=\"cta_preferred_multiple_contextual\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">Start investing in legacies, not executives. Discover our 19 top founder-led companies</a>.</p> <h3>Upgrade Your Decision Making: Choose your HA Sustainable Infrastructure Capital Narrative</h3> <p>Earlier we mentioned that there is an even better way to understand what you are paying for, so let us introduce you to Narratives, a simple way to link the story you believe about HA Sustainable Infrastructure Capital to a financial forecast and then to a fair value. On Simply Wall St‚Äôs Community page, used by millions of investors, a Narrative is your own explanation behind the numbers, where you set assumptions for future revenue, earnings and margins, and the platform converts that into a fair value that you can compare with the current share price to help you assess whether the stock looks worth buying, holding or selling. Narratives are not static, they update when fresh information such as news or earnings is added, so your fair value view can move with the company‚Äôs story. For example, one HA Sustainable Infrastructure Capital Narrative might assume stronger project growth and assign a higher fair value, while another might assume more conservative funding conditions and arrive at a lower fair value.</p> <p>Do you think there's more to the story for HA Sustainable Infrastructure Capital? <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative_community\" href=\"https://simplywall.st/stock/NYSE/HASI\" rel=\"noopener noreferrer\" target=\"_blank\">Head over to our Community to see what others are saying!</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/diversified-financials/nyse-hasi/ha-sustainable-infrastructure-capital\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:HASI 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/16359f8c-34f4-4302-89a7-1159e60d9e78/chart/quote-price?date=2026-02-27\" width=\"746\"/></a><figcaption>NYSE:HASI 1-Year Stock Price Chart</figcaption></figure> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if HA Sustainable Infrastructure Capital might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/us/diversified-financials/nyse-hasi/ha-sustainable-infrastructure-capital/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-02-28 00:00:55",
            "link": "https://simplywall.st/stocks/us/diversified-financials/nyse-hasi/ha-sustainable-infrastructure-capital/news/is-ha-sustainable-infrastructure-capital-hasi-pricing-reflec-1",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Soilbuild Construction Group (SGX:ZQM) Margin Expansion Reinforces Bullish Community Narratives",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Soilbuild Construction Group (SGX:ZQM) has just posted its FY 2025 numbers with first half revenue of S$272.8 million and basic EPS of S$0.0427, set against trailing twelve month revenue of S$590.7 million and EPS of S$0.3845 that reflect a 139.4% lift in earnings over the past year. Over the last three reported halves, revenue has moved from S$153.9 million in 1H 2024 to S$237.9 million in 2H 2024 and then to S$272.8 million in 1H 2025. Basic EPS has stepped from S$0.0125 to S$0.0290 and then to S$0.0427, with trailing net margins improving from 6.8% to 10.8%. This sets up this result as a clean read on how the improved profitability trend is holding up.</p> <a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis_earnings\" href=\"https://www.simplywall.st/stocks/sg/capital-goods/sgx-zqm/soilbuild-construction-group-shares\" rel=\"noopener noreferrer\" target=\"_blank\">See our full analysis for Soilbuild Construction Group.</a> <p>With the headline numbers on the table, the next step is to consider how this earnings run rate lines up with the prevailing narratives about growth, quality, and risk that investors have been using to frame Soilbuild Construction Group.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_generic_community_narrative\" href=\"https://simplywall.st/features/community-narratives\" rel=\"noopener noreferrer\" target=\"_blank\">Curious how numbers become stories that shape markets? Explore Community Narratives</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/sg/capital-goods/sgx-zqm/soilbuild-construction-group-shares/past\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"SGX:ZQM Revenue &amp; Expenses Breakdown as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/9ef2a928-d1a0-44fb-9b4a-f2e233954a49/chart/revenue-and-expenses-breakdown?date=2026-02-27\" width=\"746\"/></a><figcaption>SGX:ZQM Revenue &amp; Expenses Breakdown as at Feb 2026</figcaption></figure> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>139.4% earnings lift backs higher margins</h2> <ul> <li>Over the last 12 months, net income reached S$63.6 million on S$590.7 million of revenue, which lines up with the 139.4% earnings growth figure and a trailing net margin of 10.8% compared with 6.8% a year earlier.</li> <li>What stands out for a bullish view is that this higher margin is being earned on a bigger base, with revenue over the last three halves moving from S$153.9 million to S$237.9 million to S$272.8 million. This supports the idea of stronger profitability but also raises the question of how repeatable that combination is if project mix or costs shift.</li> </ul> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_consensus_narrative_link\" href=\"https://simplywall.st/stock/SGX/ZQM\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>üìä Read the what the Community is saying about Soilbuild Construction Group.</strong></a></p> <h2>EPS and profits step up each half</h2> <ul> <li>At the half year level, net income rose from S$7.4 million in 1H 2024 to S$19.2 million in 2H 2024 and S$28.3 million in 1H 2025, while basic EPS moved from S$0.0125 to S$0.0290 and then to S$0.0427 over the same three halves.</li> <li>Bulls point to this steady step up as a sign of improving earnings quality, and the trailing basic EPS of S$0.3845 versus the latest half year EPS of S$0.0427 highlights how much of the past year‚Äôs profit came from outside just this single half. Bullish investors may see this as helpful support for the view that the recent strength is not tied to a one off quarter, even though future periods will still need to back that up.</li> </ul> <h2>P/E of 10.6x versus peers at 20x</h2> <ul> <li>With the share price at S$1.02 and the provided P/E at 10.6x, the stock is described as trading below both the cited peer average P/E of 20x and the SG construction industry average of 14.2x, and also below the DCF fair value of about S$3.00.</li> <li>Supporters of a bullish stance argue that this lower multiple, alongside trailing net income of S$63.6 million and a 10.8% margin, supports the case that investors are paying less for each dollar of recent earnings. The cited forecasts of roughly 10.2% earnings growth and 12.4% revenue growth also indicate that expectations are not zero, so the valuation still assumes the business can at least hold close to its current profitability.</li> </ul> <h2>Next Steps</h2> <p>Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Soilbuild Construction Group's <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_dont_exist\" href=\"https://www.simplywall.st/stocks/sg/capital-goods/sgx-zqm/soilbuild-construction-group-shares/past\" rel=\"noopener noreferrer\" target=\"_blank\">growth</a> and its <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_dont_exist\" href=\"https://www.simplywall.st/stocks/sg/capital-goods/sgx-zqm/soilbuild-construction-group-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">valuation</a> to see if today's price is a bargain. Add the company to your <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_dont_exist\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_dont_exist\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> now so you don't miss the next big move.</p> <p>If this mix of stronger margins and a lower P/E has you thinking, it is worth checking the figures yourself and deciding how comfortable you are with the current story. To see what the optimism is focused on, take a look at <a class=\"company-report-links\" data-vars-link-type=\"cta_rewards_analysis\" href=\"https://www.simplywall.st/stocks/sg/capital-goods/sgx-zqm/soilbuild-construction-group-shares\" rel=\"noopener noreferrer\" target=\"_blank\">5 key rewards</a> and weigh it up against your own expectations.</p> <h2>Explore Alternatives</h2> <p>Even with the stronger recent margins, the wide gap between the latest half year EPS of S$0.0427 and trailing EPS of S$0.3845 leaves questions about how consistent this earnings profile really is.</p> <p>If you want ideas that may offer a more reassuring balance between earnings power and price, take a few minutes to scan through <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/global\" rel=\"noopener noreferrer\" target=\"_blank\">326 resilient stocks with low risk scores</a> and see whether any of those steadier names fit better with your comfort level.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 00:00:55",
            "link": "https://simplywall.st/stocks/sg/capital-goods/sgx-zqm/soilbuild-construction-group-shares/news/soilbuild-construction-group-sgxzqm-margin-expansion-reinfor",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Comfort Systems USA Insiders Sell Stock After Record Results And Promotions",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Multiple Comfort Systems USA (NYSE:FIX) insiders, including the CFO and several directors, recently sold significant amounts of stock.</li> <li>The transactions came shortly after the company reported record earnings and announced major executive promotions.</li> <li>The activity follows growing involvement in technology and data center projects across the business.</li> </ul> <p>These insider moves arrive after a powerful run in NYSE:FIX, with the stock at $1,438.23 and very large multi year returns, including roughly 7x over three years and more than 20x over five years. Shares are also up 4.7% over the past week, 23.9% over the past month, 43.3% year to date, and 304.7% over the past year, which can make any insider selling stand out more to investors.</p> <p>For you as a shareholder or potential buyer, the key question is how to interpret selling that comes on the heels of record results, leadership changes, and heavier exposure to technology and data center work. This article looks at what is known about the trades, how they compare with Comfort Systems USA's recent momentum, and what issues you may want to monitor next.</p> <p>Stay updated on the most important news stories for <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://www.simplywall.st/stocks/us/capital-goods/nyse-fix/comfort-systems-usa/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Comfort Systems USA</a> by adding it to your <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>. Alternatively, explore our <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/stock/NYSE/FIX\" rel=\"noopener noreferrer\" target=\"_blank\">Community</a> to discover new perspectives on Comfort Systems USA.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/capital-goods/nyse-fix/comfort-systems-usa\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:FIX 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/53688e78-b205-4ace-8db4-4ad27d1365eb/chart/quote-price?date=2026-02-27\" width=\"746\"/></a><figcaption>NYSE:FIX 1-Year Stock Price Chart</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_news_ownership\" href=\"https://www.simplywall.st/stocks/us/capital-goods/nyse-fix/comfort-systems-usa/ownership\" rel=\"noopener noreferrer\" target=\"_blank\">See which insiders are buying and buying and selling Comfort Systems USA following this latest news.</a></p> <p>Insider selling right after record results and a big run in the share price can look unsettling, but it often reflects personal portfolio decisions rather than an outright negative view on the business. At Comfort Systems USA, the CFO and two directors monetised shares shortly after the company reported very strong fourth quarter and full year 2025 numbers, highlighted an expanded US$11.94b backlog, and saw its stock move to very high levels. The CFO‚Äôs sale was sizeable in dollar terms, which tends to draw extra attention, especially when the stock has posted very large multi year returns and is trading near its highs. At the same time, Comfort Systems has just lifted its quarterly dividend from US$0.60 to US$0.70, which points to management confidence in the company‚Äôs cash generation. For you, the tension is between insiders taking some money off the table and a business that has just reported strong earnings, raised its dividend, and is deeply involved in data center and technology related projects that many investors view as long term themes.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>How This Fits Into The Comfort Systems USA Narrative</h3> <ul> <li>The record earnings, large backlog and stronger dividend fit with the narrative of Comfort Systems USA benefiting from reshoring capex, modular construction and technology driven projects.</li> <li>Heavy insider selling, particularly by the CFO, touches on one of the risks in the narrative that concentrates a lot of growth in large, complex technology and data center projects, which could face sector specific slowdowns.</li> <li>The increased focus on AI infrastructure and data centers, and the recent index inclusion, go further than the earlier narrative, which focused mainly on modular construction, reshoring and service revenue.</li> </ul> <p>Knowing what a company is worth starts with understanding its story.\n<a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/narratives/l6px86ww-industrial-reshoring-and-modular-demand-will-drive-results-into-2026\" rel=\"noopener noreferrer\" target=\"_blank\"> Check out one of the top narratives in the Simply Wall St Community for Comfort Systems USA</a> to help decide what it's worth to you.</p> <h3>The Risks and Rewards Investors Should Consider</h3> <ul> <li>‚ö†Ô∏è Concentration in technology and data center projects could become a problem if those end markets slow, given the size of the current backlog tied to these areas.</li> <li>‚ö†Ô∏è Recent significant insider selling, including by the CFO, breaks a pattern of limited insider selling over prior quarters and may signal that management sees the current share price as an attractive level to trim exposure.</li> <li>üéÅ Earnings and revenue for 2025 were much higher than a year earlier, and the backlog of US$11.94b provides multi year visibility across mechanical, electrical and modular projects.</li> <li>üéÅ The higher quarterly dividend of US$0.70 per share suggests management is comfortable returning more cash to shareholders while still funding growth in modular and service operations.</li> </ul> <h3>What To Watch Going Forward</h3> <p>From here, keep an eye on the pattern of insider activity, not just one off sales. Repeated large disposals across several executives could carry a different signal to occasional profit taking. It is also worth tracking how much of the US$11.94b backlog is tied to technology and data center work versus more diversified commercial and industrial projects, as that mix affects both risk and margin potential. Finally, watch how Comfort Systems USA converts that backlog into revenue and cash flow while supporting higher dividends and any future capital returns, especially as it competes with other large contractors such as EMCOR Group and Quanta Services for complex projects.</p> <p>To ensure you're always in the loop on how the latest news impacts the investment narrative for Comfort Systems USA, head to the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stock/NYSE/FIX\" rel=\"noopener noreferrer\" target=\"_blank\"> community page for Comfort Systems USA</a> to never miss an update on the top community narratives.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-02-28 00:00:55",
            "link": "https://simplywall.st/stocks/us/capital-goods/nyse-fix/comfort-systems-usa/news/comfort-systems-usa-insiders-sell-stock-after-record-results",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "A Look At Faraday Copper‚Äôs Valuation As CA$100m Private Placement Draws Major Mining Investors",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Faraday Copper (TSX:FDY) drew fresh investor attention after announcing a non brokered private placement of 23,810,000 common shares at CA$4.20, targeting proceeds of about CA$100m with participation from industry backed investors.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/ca/materials/tsx-fdy/faraday-copper-shares\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Faraday Copper.</a></p> <p>The private placement news has arrived while momentum in Faraday Copper‚Äôs share price has been strong, with a 7 day share price return of 58.06% and a 90 day share price return of 172.22%, alongside a very large 1 year total shareholder return that far exceeds its 3 year total shareholder return multiple.</p> <p>If this move in Faraday Copper has you looking across the copper space, you might want to scan our screener of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_copper\" href=\"https://simplywall.st/discover/investing-ideas/473751/top-copper-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">8 top copper producer stocks</a> as potential next ideas to research.</p> <p>With the share price now above the CA$4.20 placement level and trading at a premium to the CA$4.72 analyst price target, investors may wish to consider whether there is still a buying opportunity available or whether the market is already pricing in future growth.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Price to Book of 20.9x: Is It Justified?</h2> <p>Faraday Copper currently trades on a P/B of 20.9x, with the last close at CA$5.39, which sits well above the peer and industry benchmarks in the data.</p> <p>P/B compares the share price to the book value of equity per share, so it is often used for asset heavy sectors like metals and mining, where balance sheet assets and reserves matter more than near term earnings. For Faraday Copper, this high P/B multiple is sitting against a backdrop of no reported revenue, a net loss of CA$25.97m and forecasts that the company will remain unprofitable over the next three years.</p> <p>Against its direct peers, Faraday Copper screens as good value on this metric, with its 20.9x P/B sitting below the peer average of 44.6x. However, when you widen the lens to the broader Canadian metals and mining industry, which sits at 3.8x, the same 20.9x looks expensive, suggesting the market is applying a much richer multiple than the wider group.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_preferred_multiple_cta\" href=\"https://www.simplywall.st/stocks/ca/materials/tsx-fdy/faraday-copper-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">See what the numbers say about this price ‚Äî find out in our valuation breakdown.</a></p> <p><strong>Result: Price to book of 20.9x (ABOUT RIGHT versus peers, OVERVALUED versus the wider industry)</strong></p> <p>However, you are still backing an exploration stage company with no revenue and a CA$25.97m net loss, so funding conditions or project setbacks could quickly challenge this pricing.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/ca/materials/tsx-fdy/faraday-copper-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Faraday Copper narrative.</a></p> <h2>Next Steps</h2> <p>If this all feels finely balanced, it makes sense to look at the numbers yourself and move quickly to shape your own view. You can also check our breakdown of <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_analysis\" href=\"https://www.simplywall.st/stocks/ca/materials/tsx-fdy/faraday-copper-shares\" rel=\"noopener noreferrer\" target=\"_blank\">5 important warning signs</a> to see what could matter most for your decision.</p> <h2>Looking for more investment ideas?</h2> <p>If you are serious about building a stronger portfolio, do not stop at one copper name. Use the Simply Wall Street Screener to pressure test your ideas and uncover opportunities you might otherwise miss.</p> <ul> <li>Spot potential bargains early by hunting through our list of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/ca\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 6 high quality undiscovered gems</a> that combine quality fundamentals with under the radar profiles.</li> <li>Prioritise resilience by scanning <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/ca\" rel=\"noopener noreferrer\" target=\"_blank\">7 resilient stocks with low risk scores</a> that score well on key risk checks and may help steady the ride across your broader holdings.</li> <li>Strengthen your core holdings by reviewing <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_solid_balance_sheet\" href=\"https://simplywall.st/discover/investing-ideas/10146/solid-balance-sheet-and-fundamentals/ca\" rel=\"noopener noreferrer\" target=\"_blank\">solid balance sheet and fundamentals stocks screener (10 results)</a> that pair financial stability with fundamentals you can scrutinise in detail.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-02-27 23:56:02",
            "link": "https://simplywall.st/stocks/ca/materials/tsx-fdy/faraday-copper-shares/news/a-look-at-faraday-coppers-valuation-as-ca100m-private-placem",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Why Peloton Interactive (PTON) Is Down 7.7% After Forecasting a Fifth Year of Revenue Declines - And What's Next",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>In recent updates, Peloton‚Äôs leadership indicated that revenue is expected to fall again in fiscal 2026, marking a fifth straight annual decline, even as cost cuts, layoffs and lower net debt have supported positive free cash flow.</li> <li>This combination of shrinking sales but improving balance sheet strength and cash generation underscores a business in transition, where profitability gains are emerging without a clear path back to growth.</li> <li>Next, we‚Äôll examine how management‚Äôs expectation of another year of revenue decline could reshape Peloton‚Äôs investment narrative and long-term appeal.</li> </ul><p>Capitalize on the AI infrastructure supercycle with our selection of the <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473744/ai-infrastructure-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">33 best 'picks and shovels' of the AI gold rush</a> converting record-breaking demand into massive cash flow.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Peloton Interactive Investment Narrative Recap</h2><p>To own Peloton today, you have to believe that its shift from a hardware-led story to a leaner, subscription and wellness-focused platform can offset ongoing revenue declines. The latest guidance for a fifth straight year of falling sales directly pressures the key short term catalyst, which is stabilizing subscriptions, while reinforcing the biggest risk: that demand for Peloton‚Äôs ecosystem continues to soften despite cost cuts and positive free cash flow.</p> <p>The most relevant update here is management‚Äôs fiscal 2026 revenue outlook of US$2.40‚Äì2.44 billion, which confirms another year of top line contraction. This guidance sits uncomfortably beside earlier hopes that new offerings in areas like holistic wellness and commercial partnerships could support a revenue base closer to flat, and it puts more weight on whether those initiatives can eventually slow subscription losses and revive member engagement.</p> <p>Yet behind the improving free cash flow, investors should be aware of the risk that ongoing hardware and subscription declines could...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/consumer-durables/nasdaq-pton/peloton-interactive/34aujxkl-pton-major-product-overhaul-and-ai-integration-will-drive-user-experience-forward\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Peloton Interactive (it's free!)</a></p><p>Peloton Interactive's narrative projects $2.5 billion revenue and $113.2 million earnings by 2028. This implies a 0.4% yearly revenue decline and an earnings increase of about $232 million from -$118.9 million today.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/consumer-durables/nasdaq-pton/peloton-interactive/34aujxkl-pton-major-product-overhaul-and-ai-integration-will-drive-user-experience-forward\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Peloton Interactive's forecasts yield a $8.08 fair value</a>, a 98% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/consumer-durables/nasdaq-pton/peloton-interactive\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"PTON 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/0badde7c-6eac-4c07-90bf-e4b2e0580733/chart/quote-price\" width=\"746\"/></a><figcaption>PTON 1-Year Stock Price Chart</figcaption></figure> <p>Before this guidance, the most optimistic analysts were assuming Peloton could reach about US$2.7 billion in revenue and roughly US$211 million in earnings by 2028, which is a far more upbeat story than the current picture of shrinking sales. When you set that against the fresh forecast of another revenue drop and the continued pressure on hardware and subscriptions, it shows how far opinions can stretch and why it is worth weighing several different views on what happens next.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/consumer-durables/nasdaq-pton/peloton-interactive\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 8 other fair value estimates on Peloton Interactive</a> - why the stock might be worth just $4.00!</p><h2>The Verdict Is Yours</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your Peloton Interactive research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/consumer-durables/nasdaq-pton/peloton-interactive\" rel=\"noopener noreferrer\" target=\"_blank\">4 key rewards and 1 important warning sign</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/consumer-durables/nasdaq-pton/peloton-interactive\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Peloton Interactive research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Peloton Interactive's overall financial health at a glance.</li></ul><h2>Searching For A Fresh Perspective?</h2><p>Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:</p><ul><li>The future of work is here. Discover the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473746/robotics-andamp-automation-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">29 top robotics and automation stocks</a> leading the charge in AI-driven automation and industrial transformation.</li><li>We've uncovered the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> yielding 5%+ that don't just survive market storms, but thrive in them.</li><li>Rare earth metals are the new gold rush. Find out which <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 stocks are leading the charge</a>.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-27 23:56:02",
            "link": "https://simplywall.st/stocks/us/consumer-durables/nasdaq-pton/peloton-interactive/news/why-peloton-interactive-pton-is-down-77-after-forecasting-a",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "A Look At Rush Enterprises (RUSH.A) Valuation After Its Fourth Quarter Earnings Beat And Dividend Announcement",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Rush Enterprises (RUSH.A) is back in focus after fourth quarter results and a fresh dividend declaration, as investors weigh solid aftermarket performance, cost control and share repurchases against softer revenue and earnings figures.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/capital-goods/nasdaq-rush.a/rush-enterprises\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Rush Enterprises.</a></p> <p>The earnings beat and dividend announcement come against a share price of US$71.65, with a 30 day share price return of 14.24% and a 90 day gain of 37.63%. The 5 year total shareholder return of 164.85% suggests momentum has been building over a longer horizon.</p> <p>If this update has you thinking about what else is moving in related areas, it could be a good moment to broaden your search with <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_founder_led\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">19 top founder-led companies</a>.</p> <p>With the shares up strongly over the past year, a value score of 5, an intrinsic value estimate suggesting the stock trades at a discount, and a price still below the average analyst target, investors may ask whether there is still a buying opportunity or whether the market is already pricing in future growth.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Most Popular Narrative: 8.9% Undervalued</h2> <p>Rush Enterprises last closed at $71.65 versus a widely followed fair value of about $78.67, which puts the spotlight firmly on how future earnings and buybacks might interact.</p> <blockquote> <p><em>Industry wide dealer consolidation and increased truck complexity continue to favor national scale operators like Rush, allowing the company to capture greater market share and purchasing power, supporting long term revenue growth and earnings leverage as operational efficiencies scale.</em></p> </blockquote> <p><em><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/zv0012zi-trade-policy-clarity-and-e-commerce-trends-will-boost-aftermarket-demand-fr64\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></em></p> <p>Curious what earnings path, margin profile, and share count assumptions have to line up to support that fair value, especially with 2026 in focus and buybacks in the mix? The full narrative lays out how those moving parts connect and what kind of profit multiple that implies.</p> <p><strong>Result: Fair Value of $78.67 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/zv0012zi-trade-policy-clarity-and-e-commerce-trends-will-boost-aftermarket-demand-fr64\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, this hinges on conditions holding up, since extended freight softness or tougher emissions rules could squeeze truck demand, margins, and the assumptions behind that 8.9% discount.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/capital-goods/nasdaq-rush.a/rush-enterprises\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Rush Enterprises narrative.</a></p> <h2>Next Steps</h2> <p>If this mix of positives and worries feels balanced but unresolved, do not wait for consensus. Run the numbers yourself and weigh <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/capital-goods/nasdaq-rush.a/rush-enterprises\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 1 important warning sign</a> against your own expectations.</p> <h2>Looking for more investment ideas?</h2> <p>If you are serious about sharpening your watchlist, do not stop with Rush Enterprises. Use the screener to surface other opportunities that match your style.</p> <ul> <li>Target income first and review <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_dividend\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> that could help anchor a portfolio with regular cash flows.</li> <li>Hunt for value and scan <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/us\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 24 high quality undiscovered gems</a> that the market may not be paying full attention to yet.</li> <li>Prioritise resilience and check <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/us\" rel=\"noopener noreferrer\" target=\"_blank\">80 resilient stocks with low risk scores</a> if you want potential ideas with gentler risk profiles.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-02-27 23:56:02",
            "link": "https://simplywall.st/stocks/us/capital-goods/nasdaq-rush.a/rush-enterprises/news/a-look-at-rush-enterprises-rusha-valuation-after-its-fourth",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Wilmar International (SGX:F34) Margin Improvement Challenges Cautious Community Narratives",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Wilmar International FY 2025 earnings snapshot</h2> <p>Wilmar International (SGX:F34) has kicked off FY 2025 with first half revenue of about US$32.9b and basic EPS of US$0.095, setting the tone for how the rest of the year could shape up for margins and profitability. The company has seen half year revenue move from roughly US$30.9b and EPS of US$0.093 in 1H 2024 to US$36.4b and EPS of about US$0.094 in 2H 2024, before reaching the latest 1H 2025 levels. This gives investors a clear view of how the top and bottom line have been tracking through recent periods. That backdrop, together with an improvement in net profit margin to 2.0%, frames these results as a check in on how efficiently Wilmar is converting its sales base into lasting profitability.</p> <a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis_earnings\" href=\"https://www.simplywall.st/stocks/sg/food-beverage-tobacco/sgx-f34/wilmar-international-shares\" rel=\"noopener noreferrer\" target=\"_blank\">See our full analysis for Wilmar International.</a> <p>With the headline numbers on the table, the next step is to see how this earnings profile lines up with the widely shared narratives around Wilmar's growth prospects, risks, and longer term margin story.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_generic_community_narrative\" href=\"https://simplywall.st/features/community-narratives\" rel=\"noopener noreferrer\" target=\"_blank\">Curious how numbers become stories that shape markets? Explore Community Narratives</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/sg/food-beverage-tobacco/sgx-f34/wilmar-international-shares/past\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"SGX:F34 Revenue &amp; Expenses Breakdown as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/d0a3ae0d-58bd-404b-928f-ea0747b9a22a/chart/revenue-and-expenses-breakdown?date=2026-02-27\" width=\"746\"/></a><figcaption>SGX:F34 Revenue &amp; Expenses Breakdown as at Feb 2026</figcaption></figure> <h2>Trailing 12‚Äëmonth profit reaches about US$1.4b</h2> <ul> <li>Over the last 12 months, Wilmar generated about US$70.4b in revenue and around US$1.4b in net income, which works out to a 2.0% net profit margin compared with 1.7% a year earlier.</li> <li>What stands out for a more optimistic view is that trailing earnings grew 20.6% over the past year even though the five year trend shows an average 8.6% decline each year. As a result, recent profit strength sits alongside a much weaker longer term record.\n    <ul> <li>This recent period shows net income at roughly US$1.4b on US$70.4b of sales, while the longer run data points to a multi year earnings decline, so anyone with a bullish angle needs to square that contrast.</li> <li>At the same time, the 2.0% margin is still quite thin in absolute terms, which means even small changes in costs or pricing can move profit up or down quite quickly.</li> </ul> </li> </ul> <p>Stronger recent margins and earnings growth give bulls some evidence to point to, but the longer multi year earnings decline keeps the story more balanced than a simple recovery narrative suggests. <a class=\"company-report-links\" data-vars-link-type=\"cta_consensus_narrative_link\" href=\"https://simplywall.st/stock/SGX/F34\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>üìä Read the what the Community is saying about Wilmar International.</strong></a></p> <h2>P/E of 12.3x sits between sector and peers</h2> <ul> <li>Wilmar trades on a P/E of 12.3x, which is cheaper than the Asian Food industry average of 16.1x but higher than a peer group average of 9.9x, so it sits in the middle of the pack on this simple earnings multiple.</li> <li>Critics highlight that even with this mid range P/E, there are clear financial pressure points, especially around interest coverage and dividends, that could justify the market keeping the shares on a discount to some food peers.\n    <ul> <li>The data flags that interest payments are not well covered by earnings, which can make a 12.3x multiple feel less comfortable than it looks against the wider industry at 16.1x.</li> <li>The dividend track record is described as unstable and dividend sustainability a concern, so income focused investors may treat the current yield and multiple more cautiously than a simple P/E comparison suggests.</li> </ul> </li> </ul> <h2>DCF fair value sits well above the current price</h2> <ul> <li>The current share price of S$3.52 is well below a DCF fair value estimate of about S$6.60, and the dataset also notes that this implies the shares trade roughly 46.7% below that modelled value.</li> <li>Supporters of a more positive stance point to that DCF gap and the 20.6% trailing earnings growth as reasons to consider the stock undervalued, while the same numbers also sit alongside modest forecast growth of about 3.6% a year for earnings and 4.6% a year for revenue, which keeps expectations relatively low.\n    <ul> <li>The projected 3.6% earnings growth is below the Singapore market‚Äôs expected 7.5% earnings growth, so the DCF upside does not come with especially strong growth assumptions in these forecasts.</li> <li>Because the net margin is 2.0% on roughly US$70.4b of trailing revenue, even modest growth in sales or small margin shifts can move absolute profit by hundreds of millions of US$, which partly explains why a valuation model can land so far above the current share price.</li> </ul> </li> </ul> <h2>Next Steps</h2> <p>Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Wilmar International's <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_dont_exist\" href=\"https://www.simplywall.st/stocks/sg/food-beverage-tobacco/sgx-f34/wilmar-international-shares/past\" rel=\"noopener noreferrer\" target=\"_blank\">growth</a> and its <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_dont_exist\" href=\"https://www.simplywall.st/stocks/sg/food-beverage-tobacco/sgx-f34/wilmar-international-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">valuation</a> to see if today's price is a bargain. Add the company to your <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_dont_exist\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_dont_exist\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> now so you don't miss the next big move.</p> <p>Curious whether these earnings and valuation signals point to opportunity or caution? It is worth checking the underlying data yourself and forming a view quickly, then rounding out your picture with <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/sg/food-beverage-tobacco/sgx-f34/wilmar-international-shares\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 2 important warning signs</a>.</p> <h2>See What Else Is Out There</h2> <p>Wilmar's thin 2.0% net margin, interest coverage concerns, and unstable dividend profile suggest income focused investors may want companies with more resilient financial foundations.</p> <p>If those pressure points are making you cautious, shift your attention to our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_solid_balance_sheet\" href=\"https://simplywall.st/discover/investing-ideas/10146/solid-balance-sheet-and-fundamentals/global\" rel=\"noopener noreferrer\" target=\"_blank\">solid balance sheet and fundamentals stocks screener (372 results)</a> to quickly find companies where financial strength is front and center.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if Wilmar International might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/sg/food-beverage-tobacco/sgx-f34/wilmar-international-shares/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-02-27 23:56:02",
            "link": "https://simplywall.st/stocks/sg/food-beverage-tobacco/sgx-f34/wilmar-international-shares/news/wilmar-international-sgxf34-margin-improvement-challenges-ca",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Terns Pharmaceuticals (TERN) Valuation Check After Strong Recent Share Price Run And CML Narrative Shift",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Terns Pharmaceuticals (TERN) has drawn attention after recent trading, with the stock closing at US$40.92. For investors, the clinical stage focus on oncology and obesity raises questions about how current pricing reflects trial progress and cash needs.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tern/terns-pharmaceuticals\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Terns Pharmaceuticals.</a></p> <p>While the share price slipped around 1% on the day to US$40.92, it remains on a strong short term run, with a 16.61% 1 month share price return and a 45.57% 3 month share price return, alongside a very large 1 year total shareholder return that hints at shifting expectations around trial progress and future funding needs.</p> <p>If Terns‚Äô sharp rerating has you thinking about where else high growth stories might be emerging, our screener of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_healthcare_ai\" href=\"https://simplywall.st/discover/investing-ideas/434426/healthcare-ai/us\" rel=\"noopener noreferrer\" target=\"_blank\">29 healthcare AI stocks</a> is a straightforward way to find other ideas in related areas of the market.</p> <p>With revenue still at US$0 and a US$94.435 million loss, yet a share price that has already moved sharply, the real question is whether Terns is still mispriced or if markets are already accounting for future growth.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Most Popular Narrative: 58.5% Undervalued</h2> <p>At a last close of $40.92 versus a narrative fair value of $98.57, some investors are clearly thinking the current price does not fully reflect Terns Pharmaceuticals‚Äô CML opportunity in TERN-701.</p> <blockquote> <p><em>TERN-701: A Clinically Superior Drug Poised for Market Capture<br/>The foundation of the $98.57 target is the compelling efficacy and safety seen in the Phase 1 CARDINAL trial:<br/>‚Ä¢ Global CML Market Size (Peak): The estimated size remains stable at $10 Billion.<br/>‚Ä¢ Peak Annual Sales (TERN-701): This is the core driver of the higher valuation. Based on achieving a 30% global market share (up from the previous 25% conservative estimate), the projected Peak Annual Sales for TERN-701 increase to $4.5 Billion. This capture is driven by its anticipated dominance in 2L/3L CML and its eventual entry into the massive 1L market.<br/>‚Ä¢ Probability of Success (PoS): The clinical data has significantly de-risked the program. The PoS is increased from 75% to a more confident 80%, reflecting the high likelihood of successful Phase 3 trials and regulatory approval.<br/>‚Ä¢ Net Present Value (NPV) Factor: The robust clinical de-risking and the clear blockbuster status ($1B in sales) warrant a higher valuation multiple. The Program Value is calculated using a 5.0x Peak Sales Multiple (up from 3 to 5).</em></p> </blockquote> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/yicsbbfw-update-for-terns-pharmaceuticals\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></p> <p>If you want to see what is sitting behind that $98.57 figure, the narrative according to AverageSven leans heavily on long term CML sales, ambitious market share in multiple treatment lines, and a profitability profile that aims to justify a premium valuation multiple over time. Result: Fair Value of $98.57 (UNDERVALUED)</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_user_generated_narrative\" href=\"https://www.simplywall.st/narratives/yicsbbfw-update-for-terns-pharmaceuticals\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, this depends on successful CML trial outcomes and regulatory approvals. In addition, the company still has US$0 revenue and a US$94.435 million loss to fund.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tern/terns-pharmaceuticals\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Terns Pharmaceuticals narrative.</a></p> <h2>Another View: Rich Pricing On Traditional Metrics</h2> <p>If you step away from the narrative of fair value and look at a simple P/B comparison instead, Terns trades at 15.7x book value versus 2.3x for the wider US Pharmaceuticals group and 3.6x for peers. That is a wide gap, and without revenue or profits today, it raises the question of how much future success is already baked into the price.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_preferred_multiple_cta\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tern/terns-pharmaceuticals/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">See what the numbers say about this price ‚Äî find out in our valuation breakdown.</a></p> <p></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/pharmaceuticals-biotech/nasdaq-tern/terns-pharmaceuticals/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGS:TERN P/B Ratio as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/53e84d8e-18a1-49dd-b0ed-ed1f8f45a6c3/chart/pb-multiple-vs-industry?date=2026-02-27\" width=\"746\"/></a><figcaption>NasdaqGS:TERN P/B Ratio as at Feb 2026</figcaption></figure><p> </p><h2>Next Steps</h2> <p>If this mix of confidence and concern around Terns leaves you unsure, it is worth checking the numbers yourself and forming your own view quickly, including weighing up <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tern/terns-pharmaceuticals\" rel=\"noopener noreferrer\" target=\"_blank\">1 key reward and 5 important warning signs</a>.</p> <h2>Looking for more investment ideas?</h2> <p>If Terns has caught your eye but you want a broader watchlist, it makes sense to line up a few other candidates before the next round of news hits.</p> <ul> <li>Spot potential bargains early by checking our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">54 high quality undervalued stocks</a> that pair solid fundamentals with pricing some investors may be overlooking.</li> <li>Strengthen your core holdings with <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_solid_balance_sheet\" href=\"https://simplywall.st/discover/investing-ideas/10146/solid-balance-sheet-and-fundamentals/us\" rel=\"noopener noreferrer\" target=\"_blank\">solid balance sheet and fundamentals stocks screener (41 results)</a> that focus on financial resilience and cleaner balance sheets.</li> <li>Stay ahead of the crowd with our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/us\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 24 high quality undiscovered gems</a> before they attract wider market attention.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if Terns Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/us/pharmaceuticals-biotech/nasdaq-tern/terns-pharmaceuticals/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-02-27 23:46:38",
            "link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tern/terns-pharmaceuticals/news/terns-pharmaceuticals-tern-valuation-check-after-strong-rece",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is Campbell Soup (CPB) Now Offering Value After Prolonged Share Price Weakness",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>If you are wondering whether Campbell's current share price still reflects the value of a classic consumer brand, you are not alone. This article is built to help you size that up calmly.</li> <li>At a last close of US$26.86, the stock has seen a 0.4% decline over 7 days, a 1.9% decline over 30 days, and is down 3.1% year to date, with a 29.2% decline over 1 year and a 42.5% decline over 3 years.</li> <li>These moves sit against an ongoing stream of news around packaged food companies, including debates on pricing power, consumer demand for at home meals, and brand relevance in crowded supermarket aisles. For Campbell's, those themes shape how investors think about its earnings resilience and what they are willing to pay for the stock.</li> <li>Simply Wall St currently gives Campbell's a valuation score of <a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/food-beverage-tobacco/nasdaq-cpb/campbells/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">4/6</a>, based on how it screens across several checks for being undervalued. Next, we will walk through the main valuation methods used here before finishing with a broader way to think about what that score really means over the long run.</li> </ul> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_industry_underperformer\" href=\"https://www.simplywall.st/stocks/us/food-beverage-tobacco/nasdaq-cpb/campbells/future\" rel=\"noopener noreferrer\" target=\"_blank\">Find out why Campbell's's -29.2% return over the last year is lagging behind its peers.</a></p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>Approach 1: Campbell's Discounted Cash Flow (DCF) Analysis</h3> <p>A Discounted Cash Flow, or DCF, model estimates what a business could be worth by projecting its future cash flows and then discounting them back to today using a required rate of return. It is essentially asking what those future dollars are worth in today's terms.</p> <p>For Campbell's, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The last twelve months free cash flow is reported at about $658.3 million. Analysts supply forecasts for the next few years, and Simply Wall St then extends those further, with ten year projections reaching $881.2 million in 2035, all in $ terms.</p> <p>When all those projected cash flows are discounted back, the model arrives at an estimated intrinsic value of about $59.35 per share. Compared with the recent share price of $26.86, this implies a 54.7% discount to that DCF estimate. This suggests that Campbell's may be trading below this particular assessment of its cash flow value.</p> <p><strong>Result: UNDERVALUED</strong></p> <p>Our Discounted Cash Flow (DCF) analysis suggests Campbell's is undervalued by 54.7%. Track this in your <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>, or discover <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">54 more high quality undervalued stocks</a>.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/food-beverage-tobacco/nasdaq-cpb/campbells/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"CPB Discounted Cash Flow as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/b9a9b32a-2584-4709-a4a3-d825b2a7a6f7/chart/dcf?date=2026-02-27\" width=\"746\"/></a><figcaption>CPB Discounted Cash Flow as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"dcf_explainer_cta\" href=\"https://www.simplywall.st/stocks/us/food-beverage-tobacco/nasdaq-cpb/campbells/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Campbell's.</a></p> <h3>Approach 2: Campbell's Price vs Earnings</h3> <p>For a profitable business like Campbell's, the P/E ratio is a useful shorthand for how much investors are paying for each dollar of current earnings. It captures what the market is willing to pay today for those earnings, without needing detailed forecasts.</p> <p>What counts as a \"normal\" P/E depends a lot on how investors view a company's growth prospects and risk. Higher expected growth or perceived resilience can justify a higher multiple, while slower growth or higher risk usually pulls it down.</p> <p>Campbell's currently trades on a P/E of 13.9x, compared with a Food industry average of 24.5x and a peer group average of 13.2x. Simply Wall St also calculates a proprietary \"Fair Ratio\" of 20.7x for Campbell's, which is the P/E level it might trade on given its earnings profile, industry, profit margins, market cap and specific risks.</p> <p>This Fair Ratio can be more tailored than a simple comparison to peers or the broad industry, because it adjusts for the factors that make Campbell's different rather than assuming all companies deserve the same multiple. Set against the current P/E of 13.9x, the 20.7x Fair Ratio describes Campbell's shares as screening as undervalued on this metric.</p> <p><strong>Result: UNDERVALUED</strong></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/food-beverage-tobacco/nasdaq-cpb/campbells/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGS:CPB P/E Ratio as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/b9a9b32a-2584-4709-a4a3-d825b2a7a6f7/chart/pe-multiple-vs-industry?date=2026-02-27\" width=\"746\"/></a><figcaption>NasdaqGS:CPB P/E Ratio as at Feb 2026</figcaption></figure> <p>P/E ratios tell one story, but what if the real opportunity lies elsewhere? <a class=\"company-report-links\" data-vars-link-type=\"cta_preferred_multiple_contextual\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">Start investing in legacies, not executives. Discover our 19 top founder-led companies</a>.</p> <h3>Upgrade Your Decision Making: Choose your Campbell's Narrative</h3> <p>Earlier we mentioned that there is an even better way to understand valuation, so let's introduce you to Narratives, which are simply your story about Campbell's, linked directly to your own revenue, earnings and margin assumptions, a Fair Value estimate, and then compared with the current share price to help you decide what to do.</p> <p>On Simply Wall St's Community page, Narratives are an accessible tool used by millions of investors that let you combine your qualitative view on things like scanner trends, tariffs, product relevance, snacks and meals demand, or cost savings with a structured financial forecast so your opinion is tied to actual numbers rather than vibes alone.</p> <p>Narratives are refreshed as new news, analyst targets, earnings updates, or guidance changes are entered into the model. As a result, your Fair Value view moves with the information, and you can quickly see if your story still lines up with how Campbell's is trading.</p> <p>For Campbell's, one investor might build a Narrative closer to the higher Fair Value views around US$55.33 that lean on stronger Snacks, premium products and supply chain efficiency. Another might sit near the more cautious US$26.00 Fair Value that leans on pressure from private labels, tariffs and slower processed food demand. Both investors can see in real time how their Fair Value compares to the current price.</p> <p>For Campbell's, however, we will make it really easy for you with previews of two leading Campbell's Narratives:</p> <p><a href=\"/us/food-beverage-tobacco/nasdaq-cpb/campbells/d80u9vdb-consumer-preferences-and-operational-efficiency-will-build-future-resilience-kajn?utm_medium=finance_user&amp;utm_campaign=cta_bull_narrative_link&amp;utm_source=post\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>üêÇ Campbell's Bull Case</strong></a></p> <p>Fair value in this Narrative: US$31.56</p> <p>Implied discount to this fair value at US$26.86: 14.9%</p> <p>Revenue growth assumption used: 0.58%</p> <ul> <li>Analysts in this Narrative see steady demand for soups, broths, sauces and snacks supported by at-home cooking, health-focused tweaks to recipes, and premium products.</li> <li>They build in rising profit margins over the next few years, supported by cost-savings programs, supply chain work and focused marketing on brands such as Rao's and Goldfish.</li> <li>The result is a consensus price target of US$34.58 that sits close to where shares are trading in this view, which they frame as broadly in line with their estimate of fair value.</li> </ul> <p><a href=\"/us/food-beverage-tobacco/nasdaq-cpb/campbells/xg4qpi1w-declining-processed-food-sales-and-tariffs-will-weaken-prospects-qnnl?utm_medium=finance_user&amp;utm_campaign=cta_bear_narrative_link&amp;utm_source=post\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>üêª Campbell's Bear Case</strong></a></p> <p>Fair value in this Narrative: US$26.00</p> <p>Implied premium to this fair value at US$26.86: 3.3%</p> <p>Revenue growth assumption used: 0.45% decline</p> <ul> <li>This Narrative leans into concerns that consumer preferences for fresher and private-label options keep pressuring Campbell's volumes, pricing power and category relevance.</li> <li>It places more weight on tariffs, regulatory costs and the risk that new products in soups and snacks do not fully offset headwinds, which keeps revenue growth assumptions muted.</li> <li>Using those inputs, the fair value comes out at US$26.00, which is below the recent share price and lines up with the lowest end of current analyst targets.</li> </ul> <p>If you want to see how other investors are framing stories like these, and how their numbers stack up against current pricing, <a class=\"company-report-links\" data-vars-link-type=\"cta_generic_community_narrative\" href=\"https://simplywall.st/features/community-narratives\" rel=\"noopener noreferrer\" target=\"_blank\">Curious how numbers become stories that shape markets? Explore Community Narratives</a> can be a useful next step.</p> <p>Do you think there's more to the story for Campbell's? <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative_community\" href=\"https://simplywall.st/stock/NasdaqGS/CPB\" rel=\"noopener noreferrer\" target=\"_blank\">Head over to our Community to see what others are saying!</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/food-beverage-tobacco/nasdaq-cpb/campbells\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGS:CPB 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/b9a9b32a-2584-4709-a4a3-d825b2a7a6f7/chart/quote-price?date=2026-02-27\" width=\"746\"/></a><figcaption>NasdaqGS:CPB 1-Year Stock Price Chart</figcaption></figure> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-02-27 23:46:38",
            "link": "https://simplywall.st/stocks/us/food-beverage-tobacco/nasdaq-cpb/campbells/news/is-campbell-soup-cpb-now-offering-value-after-prolonged-shar",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        }
    ]
}